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ABSTRACT
Treatment with androgens and anabolic steroids in conditions o f high bone 
turnover seen in osteoporotic postmenopausal females has resulted in bone density 
improvement. Research has demonstrated a link between muscle mass and bone due to 
the mechanical demands placed on bone by muscular contractile force associated with 
physical activity. This study examined whether treatment with a synthetic anabolic 
steroid, 30 mg. o f nandrolone decanoate every two weeks, or placebo increased lean 
mass, cross-sectional area of thigh muscle and muscle torque production while 
preserving bone mineral density (BMD) in 18 dieting, sedentary, obese, postmenopausal 
females not on estrogen replacement therapy. Obesity has been associated with greater 
BMD, however, previous work has suggested weight loss can precipitate the occurrence 
o f a decline in BMD. Data that were collected included 24-hour urinary calcium and 
phosphorusxreatinine ratios, serum osteocalcin, parathyroid hormone, total alkaline 
phosphatase and 25(OH) D3. Additionally, BMD and content (BMC) were measured in 
the lumbar spine and bilateral forearms with dual emission x-ray absorptiometry.
Subjects treated with nandrolone (n=8) demonstrated a significant treatment by time 
increase in lean body mass with a concomitant decline in % body fat, non-significant 
increase in muscle thigh volume, no significant change in fat mass and a non-significant 
decline in lumbar BMD at six months. Isokinetic muscle testing demonstrated significant 
increases in torque production and total work of the upper extremities and to a lesser extent 
the lower extremities torque. Non-significant decreases in weight and body mass index 
occurred. Overall, there were no effects of treatment on bone turnover. The small changes in 
% body fat, lean mass and torque did not have any effects on bone status. No changes
occurred in total fat mass, therefore decline in % BF occurred only due to increases in lean 
mass. Addition of exercise training to nandrolone treatment might have enhanced the 
increases in lean mass and strength, as well as fat mass loss, facilitating a greater strain-related 
stimulation for bone formation. Further research on BMD of postmenopausal women 
undergoing weight loss is indicated since they are at high risk for bone loss.
CHAPTER 1: INTRODUCTION 
When older obese women with normal bone density diet to lose weight there is a 
potential concern for loss of lean body mass as well as bone mineral density and content 
(BMD and BMC). Due to their postmenopausal state, the risk for bone loss, particularly 
trabecular bone, is high as weight declines and less adrenal adrostenedione is aromatized to 
estrone in adipose tissue. Both exercise and pharmacological agents have previously been 
investigated for their effects on the modeling and remodeling processes of bone tissue to 
determine if they can elicit a positive effect on minimizing high bone turnover 
characteristically seen in the postmenopausal state. In order to clearly understand the 
potential ramifications of significant weight loss by postmenopausal women on bone 
structure, it is important to understand the basic mechanisms of normal bone turnover, the 
coupling of resorption and formation and how these activites are controlled through 
modeling and remodeling of the skeletal system.
Mechanisms of Bone Homeostasis
The mechanism whereby bone is laid down and resorbed is a dynamic process 
under the control o f various endogenous and exogenous forces. Some of the major 
factors influencing this process are: feedback from the endocrine system,(1) nutritional 
intake of various electrolytes,<2'4) appropriate absorption o f these minerals from the 
gastrointestinal system,(5'7) estrogen status in females,(8) body weight,(9,10) movement 
creating a stress-strain relationship of bone and muscle0 0 and genetic influences.(3,I2) 
All o f these factors are interdependently associated with bone remodeling in both 
trabecular and cortical bone.
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Parathyroid hormone (PTH) is known to regulate calcium balance via direct 
action on bone. It stimulates osteoclast numbers and activity, inhibits osteoblast function 
and increases calcium renal distal tubular reabsorption from the glomerular filtrate, thus 
increasing serum calcium levels.0* PTH is also responsible for inhibition of phosphate 
reabsorption in the renal proximal tubules and regulates control o f activation o f 1,25 
(OH)2D3, the active form of vitamin D, which is responsible for increasing calcium 
absorption in the gut.(13) It is also known that vitamin D and vitamin D metabolite 
receptors are located on the parathyroid gland, to provide feedback.<14)
Calcitonin, another calcitropic hormone, acts by directly inhibiting calcium 
resorption from bone by its action on osteoclasts.(1) Specific receptors for calcitonin are 
located on osteoclasts and in renal plasma membranes.<13) Calcitonin binding to 
receptors on osteoclasts effectively inhibits resorptive actions such as mineral release 
from bone, breakdown of collagen and lysosomal enzyme changes.0*
Overall, the active process of bone remodeling involves the activity o f osteoblasts 
(initiate bone formation) and osteoclasts (create bone resorption).0* The resulting 
action which occurs from osteoblast to mineralization of the bone is highly regulated and 
a long-term process, in terms of effects on bone mineral density (BMD) and content 
(BM C)05* The constant interplay of bone turnover between osteoblasts and osteoclasts 
is normally coupled so that bone formation is favored over resorption, resulting in bone 
density remaining relatively unchanged.03* There is, however, an age-related bone 
turnover relationship which has been defined as demonstrating a peak lumbar bone 
density up until age 30-35, with a decline thereafter06*
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Relationship between Muscle Mass and Bone M ineral Density
A recurrent issue in the literature regarding dynamics of bone density is the 
suggestion that lean body mass, in the form of skeletal muscle, exerts a tremendous and 
positive influence on bone preservation and formation. It has been observed that 
paralysis and immobilization both result in muscle and bone atrophy.(17,18) Additionally, 
weightlessness yields similar effects.(19) Although no precise mechanisms have been 
identified as to the relationship between lean mass and skeletal bone density, Dalsky 
(1989) suggests that the stress-strain relationship between bone and muscle, known as 
Lanyon’s minimum effective strain-related stimulus defines that a level o f strain is 
necessary to maintain the modeling action on bone and a higher level is required for 
remodeling to occur/ 111 This force may serve to stimulate or mediate increases in 
osteoblastic activity/ 111 Conroy, et al. also assert that skeletal muscle contraction 
employs a localized force on bone, resulting in mediation of bone turnover with 
formation proportional to the load applied/ 201 Snow-Harter, et al. concluded that the 
relationship between muscle and bone is based upon muscular strength, not just mass, 
and is a much more complex issue than simple anatomy o f muscle insertion to bone/ 211
More specifically, it has been proposed that muscular strength accounts for 15% 
to as high as 50% of the variance in BMD/ 20’211 Muscle strength in the forms of 
isometric, isokinetic and isotonic contractions have all been correlated at varying levels 
with BMD/ 221 Resistance exercise training, in particular, has been observed to account 
for chronic skeletal loading, resulting in greater muscle mass and strength/ 201 Mikesky 
has observed in felines that resistance exercise increased muscle mass and strength, 
which was accounted for by an increase in cross-sectional area (CSA) of the muscle
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fibers (hypertrophy) and an increase in numbers o f new fibers (hyperplasia).(23) Muscle 
mass is a direct product o f muscle fiber weight as well as number o f myofibrils 
(contractile tissue), in addition to a smaller portion of non-contractile tissue, according 
to Gollnick, et al.(24) Changes that occur in muscle mass as a result of chronic resistance 
training are even seen with resistance training of the elderly, resulting in strength 
improvement due to hypertrophy and hyperplasia.(25)
The increase in muscle mass resulting from hypertrophy, as well as hyperplasia, 
may produce a greater strain on bone because of the greater muscle weight and its 
resulting higher contractile force. Doyle, et al. implicated muscle weight as an important 
determinant for contractile activity affecting bone mass more than 20 years ago. His 
methods were crude compared to current technology in that he excised and measured 
wet muscle and vertebral ash weights from cadavers. This was an important first step to 
identify a mechanism for muscle and bone interaction: the greater the muscle mass, the 
greater possible contractile force of muscle acting upon the dynamics of bone 
turnover.(18) Since then, muscle mass and strength have been noted to serve as 
predictors for BMD at various regional sites of the body (femoral neck, spine, wrist and 
ankle).(20,21) It has also been suggested that the positive effects o f exercise on bone 
turnover may be proportional to the magnitude of the load applied, rather than the total 
number of loading cycles.(20) It is, therefore, important to consider that if the muscle 
group is not stressed, such as with exercise, it may not potentiate an altered stress-strain 
relationship to result in any effects on bone dynamics. Since exercise training is an 
integral part o f chronic muscle fiber stimulation by neurological factors (recruitment of 
specific motor units) exercise may be a necessary component o f the biomechanical
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relationship between bone and muscle.<25) Ironically, Frontera observed that although a 
relationship between muscle mass, strength and BMD appears to exist and has been 
documented in previous research, there has been no direct nor consistent correlation 
between proximity o f the muscle stressed and regional BMD.
Study Rationale
There are a number of factors that can potentially influence bone turnover 
dynamics. Estrogen deficiency is an important factor which has clearly been documented 
to increase women’s risk for Type I Osteoporosis. The estrogen deficient female has 
been observed in longitudinal studies to lose bone during perimenopausal years, in 
addition to very rapid resorption at the rate of 2-3% per year and higher for the first 8-10 
years after menopause begins.(26) These women are also much more apt to become 
sedentary, lose muscle mass and strength as they grow older.
Additionally, decreased BMD is an important issue to the premenopausal female. 
This group may develop problems with high bone resorption as a result o f excessive 
dieting and weight loss. Lukaski suggests it may be an important concern in dieting 
females due to results from a 1993 study at a USDA Human Nutrition Research Center. 
This USDA study focused on obese premenopausal women who lost an average of 2-3% 
o f their whole body bone density, following a five month very low calorie diet 
regimen.(27) These women would be at even higher risk for osteoporosis once 
menopause begins due to the fact that they would be entering estrogen deficiency with a 
suboptimal peak BMD.
The current investigation presented in this manuscript was part o f a larger study 
evaluating the treatment effects of hypocaloric diet and anabolic steroid treatment over
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nine months on reduction in abdominal fat.(28) This research focused on musculoskeletal 
effects o f the treatment regimen. Clearly, this group of subjects faced the risk of 
accelerated bone loss due to their age and sex. The treatment regimen of the core study 
included a 500 kcal reduction in daily calorie intake from each subject’s resting metabolic 
rate with the diet based upon the ADA exchange system and a maximum intake o f fat at 
30% o f daily calories. Subjects also had a sedentary lifestyle and no estrogen 
replacement therapy or calcium supplementation. Because of their postmenopausal 
status, these women were at some risk for bone loss with weight reduction.
Anabolic steroids have been utilized in various groups o f subjects from the 
nutritionally debilitated individual, to osteoporotic post-fracture patients, to the more 
publicized abuse by athletes. This particular investigation focused on anabolic treatment 
effects increasing lean mass, which has typically been observed. Previous research has 
suggested anabolic steroids could be valuable in the treatment and prevention of 
osteoporosis due to its effect on muscle mass and direct load on the bone.<18) Because 
anabolic steroids facilitate an increase in muscle mass (presumably through hypertrophy 
of the contractile fibers resulting in a greater potential load on the skeleton) these effects 
on muscle mass and bone were selected as the focus of the current investigation.
Purpose of the Study
The purpose o f this investigation was to test the hypothesis that treatment with a 
synthetic anabolic steroid, nandrolone decanoate, results in increased lean mass with 
increased muscle torque production and a pattern o f BMD and BMC preservation or 
improvement, in dieting obese postmenopausal females with normal bone density. Drug 
treatment o f the research subjects was accomplished by the administration o f either
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30 mg. o f nandrolone decanoate or a placebo of equal amount administered parenterally 
every two weeks in a double-blind fashion.
Because muscle mass, strength and bone turnover status as a result o f anabolic 
steroid treatment were important concerns, there were four predominant issues in this 
study.
First, a significant issue was to observe whether diet and anabolic steroid 
treatment would result in an increase in lean mass and loss of fat mass. Second, it was 
important to assess whether BMD could be preserved or increased. Third, assessment o f 
change in maximal muscle force (torque) production was important due to the potential 
changes in lean mass. Fourth, bone remodeling effects from anabolic treatment and diet 
were examined to observe whether increasing lean mass, independent o f exercise, had 
any effect on BMD in an estrogen deficient sample. Evaluation of potential changes in 
muscle CSA was of particular interest due to the drug treatment since anabolic steroids 
are known to exert a direct effect by increasing lean mass. It was imperative to observe 
for potential changes through a number of avenues: radiologically, with biochemical 
markers o f bone turnover and endocrine responses.
Specific Aims
To test the hypothesis, specific aims were developed for the nine month 
investigation, which identified biomechanical, biochemical, endocrine and radiological 
endpoints.
Aim 1: To document body composition changes over the nine month study, 
specifically by determining weight, lean and fat mass, % body fat (% BF), cross-sectional
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area (CSA) of the left thigh, body mass index (BMI), arm circumference (AC) and 
waist:hip ratio (WHR).
•  Body composition was evaluated to note if any anthropometric changes in lean and 
fat mass occurred over time due to treatment. Specifically, it was hypothesized that 
lean mass (total body and CS A o f the thigh) would increase and % BF, BM, BMI, 
AC and WHR would decrease due to anabolic steroid treatment while fat mass 
would decrease as a result o f diet intervention.
Aim 2: To compare treatment and placebo effects, without exercise training, with 
respect to alterations in maximal muscle force production in both the upper and lower 
extremities.
• Maximal force production was selected as a dependent variable to document any 
changes resulting from hypertrophy of the muscle tissue secondary to treatment with 
nandrolone decanoate versus placebo. It was hypothesized that a pattern of 
increased muscle torque production would accompany an increase in lean body mass 
due to nandrolone treatment while the placebo group muscle torque production 
would decline.
Aim 3: To assess biochemical and endocrine patterns of bone turnover, over nine 
months, in response to treatment with nandrolone versus placebo.
•  Urinary levels o f calcium and phosphorus were selected as dependent variables 
because they are indicative o f endocrine control of bone homeostasis, as well as 
reflecting dietary intake o f these minerals. PTH, 25 (OH) D3, total alkaline 
phosphatase (Aik Phos) and osteocalcin levels were evaluated because of their role in 
bone remodeling, thus having been used previously as markers for bone turnover. As
noted previously, PTH and vitamin D are known as calcitropic hormones, which are 
responsible for the major portion of endocrine control (PTH-Vitamin D axis) o f bone 
mineral turnover/4’ Osteocalcin (bone Gla-protein) represents osteoblastic activity at 
the bone cellular level, in terms of remodeling. Aik Phos reflects turnover due to 
osteoblastic activity in the bone and is also released from the liver and is proposed to 
be a marker for bone formation in the serum. It was hypothesized that the following 
pattern would be observed in subjects treated with nandrolone: a decrease in urinary 
loss of calcium and phosphorus: creatinine, a decline in PTH, a rise in osteocalcin, 
alkaline phosphatase and elevated 25 (OH) D3. Vitamin D (25 (OH) D3) may be 
elevated if calcium homeostasis is improved. However, 25 (OH) D3 was primarily 
measured to assess vitamin D status in all subjects.
Aim 4: To document changes in bone mineral density and content (BMD and BMC) 
in both trabecular and cortical bone (spine and forearms ) as a response to treatment with 
nandrolone versus placebo over nine months.
•  Selection o f these endpoints were important due to potential regional skeletal effects 
on BMD and BMC of trabecular and cortical bone from anabolic steroid treatment.
It was hypothesized that BMD and BMC of the spine and forearms would be 
preserved and possibly increased with nandrolone treatment whereas the placebo 
group would demonstrate a decline.
Implications
Results from this study will improve our ability to identify systemic and 
mechanistic effects on bone remodeling in response to anabolic steroid treatment. 
Although anabolic steroids have been utilized previously in clinical treatment of
osteoporosis, there is little evidence as to how they inhibit bone resorption and enhance 
bone deposition. Perhaps by using the model o f the postmenopausal subject with normal 
bone density, the actions o f this class of drugs can be better understood. Data on muscle 
mass and maximal muscle torque changes gleaned from this investigation could be 
exceedingly useful since it is the older subject who benefits most from increases in 
muscle mass and force due to improvement in gait, balance, ability to ambulate and 
greater independence with activities o f daily living. Finally, those women who are not 
suitable candidates for estrogen replacement therapy may be candidates for low dose 
anabolic steroid treatment for preservation of both muscle and bone mass.
CHAPTER 2: REVIEW OF LITERATURE 
This chapter reviews the current and significant recent scientific literature in the 
areas o f the 1) physiology of bone turnover processes, 2) relationship between muscle 
strength and biomechanical load on the skeletal system (systemically and regionally) and 
3) the process of osteoporosis as defined by biochemical markers o f bone turnover. 
Discussion o f various pharmacological interventions used in the current treatment of 
osteoporosis is reviewed. Additionally, there is discussion o f the action o f anabolic 
steroids on muscle tissue and their role in bone mass improvement in osteoporosis 
treatment. Lastly, discussion focuses on the present study, treatment with nandrolone 
decanoate and its use in previous osteoporosis research.
Factors Associated with Bone Turnover
Prediction o f bone density in individuals is based upon a number o f 
interdependent factors. Although many factors that influence bone density have been 
identified (including age, sex, race, genetics, estrogen deficiency, calcium intake, vitamin 
D3, PTH and osteocalcin levels, exercise, muscle force production, immobility, familial 
history of low bone density or osteoporosis, smoking, alcohol intake and administration 
o f various medications), none are believed to serve as an independent predictor of bone 
density.(5‘!3) In particular, exercise has been studied extensively for its effect on lean 
mass, since increasing muscle mass with resultant improvement in contractile force may 
serve to directly increase forces on the bone. The enhanced biomechanical force on the 




Observations have been made o f exercise training effects on bone mineral density 
and bone mineral content changes, although a specific causal mechanism has yet to be 
identified. Cross-sectional studies have shown an association between level of physical 
activity and bone mineral density.(29,30) Dalsky suggests that exercise training may 
increase peak bone mass by as much as 10% and this effect is indirectly related to 
Lanyon’s minimum effective strain-related stimulus/11,29) Weight-bearing exercise, which 
creates a mechanical load on the skeleton and improves bone density, has been an 
extensively discussed issue in the literature.01,18'29’31'331 Post-mortem studies by Doyle, 
Brown and Lachance showed a strong correlation (r = 0.72) between psoas muscle 
weight and the ash weight of the L3 vertebrae. From these data, they concluded that 
greater muscle mass, with its associated higher contractile force exhibited in physical 
activity, serves to exert a greater direct force on the skeleton than smaller muscle mass 
and is therefore a major determinant of bone mass.081 Conversely, muscle disuse and 
resulting atrophy, reflecting decreased muscle contractile force, may negatively affect 
bone density in elderly patients/ 341 Vastus lateralis muscle biopsies from hip fracture 
patients during surgical repair o f the femur revealed a significant decrease in fiber size, as 
documented by use of a histological grading scale for muscle fiber atrophy. This was 
particularly evident in the fast-twitch fibers/ 341 Heavy resistance exercise appears to 
have more consistently resulted in muscle hypertrophy and bone mineral density increase 
over non-loading isometric and aerobic exercise/ 32,35'391 Development of muscle fiber 
hyperplasia and hypertrophy as a consequence of resistance training has been well
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documented in animals.(23,40> There are stii! many questions as to whether resistance and 
aerobic training may result in regional or systemic skeletal changes in bone density.<30’41)
Exercise training effects on modulation of neuroendocrine responses which are 
involved with bone remodeling is one final issue which deserves consideration.
Although, there are numerous hormonal responses secondary to acute bouts o f 
endurance exercise, few o f the hormones that respond are those which are normally 
related to bone metabolism. Growth hormone (GH), for example, is known to increase 
with exercise although a less dramatic rise is observed in trained subjects/42* Since there 
is no chronic increase in GH observed with training, it is questionable but possible that 
the altered pulsatility o f GH may in some way participate in remodeling for bone 
preservation. There is also an increased turnover o f T3 and T4 during exercise, with a 
reduced concentration of T3 and free thyroxine at rest.<42) Trained subjects also elicit 
slight elevations of cortisol during exercise and males exhibit depressed testosterone 
levels.(42) Chronically elevated levels of cortisol and thyroid hormone as well as 
depressed testosterone in males would most likely not serve as a positive influence on 
bone homeostasis and therefore a causal relationship between endurance training and 
bone formation should be cautiously interpreted until further data becomes available.
In line with these thoughts, in a 1993 study with trained marathon runners using 
endurance exercise after a period of a three-week training break, Klausen, et al. assessed 
responses o f the calcitropic hormones PTH, 25 (OH) D3, 1,25 (OH)2 D3 and calcitonin. 
He observed a significant decline in 1,25 (OH)2D3 while PTH rose significantly.
Transient significant reductions in serum calcium and calcitonin were documented with a 
non-significant drop in 25 (OH) D3. Klausen concluded that a mechanism for inhibition
14
of 1-a hydroxylation of 25 (OH) D3 may occur with intensified endurance training but 
did not postulate the specific mechanisms nor justify the decline in calcitonin and rise in 
PTH.(43) It appears at this time that there is no causal relationship defined between 
endurance exercise and neuroendocrine responses which may modulate bone remodeling.
Additionally, resistance exercise has been studied for its effects on hormonal 
responses. Most resistance training studies thus far have not demonstrated an increase in 
testosterone levels in females, as well as there are conflicting results on responses of 
testosterone:cortisol ratios.(40) Elevated serum cortisol levels have been observed to 
occur following heavy bouts o f resistance exercise although these levels do not remain 
chronically high.(40) These results indicate potentially negative effects on bone status, 
rather than positive influences due to the specific trends which have been documented. 
Obviously, further research in the area of resistance training, in terms of both acute and 
chronic exercise effects on the hormonal milieu need to be addressed before any 
conclusions can be drawn regarding muscle and bone synthesis from this area o f the 
literature.
Muscle Strength
Significant correlations between muscle strength and bone density have been 
observed in human studies.(44) More specifically, muscle strength as measured 
isotonically and isokinetically are good predictors of localized bone density/22’ In 
females trunk and left knee extensor (quadriceps) strength demonstrated a moderate 
relationship to bone mass (r =0.40 and 0.49, p = 0.0001, respectively)/22’ Rutherford 
and Jones have also observed a relationship between knee extensors muscle strength and 
cross sectional area and femoral BMD in the elderly/45’
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Grip strength has also been found to correlate with BMC of the forearm (r= 
0.66, p < 0.001).(4(>) Less robust results were obtained by Bevier with observed 
correlation between grip strength, forearm (radius and ulna) and spine (lumbar) density 
in women (r = 0.37, r = 0.28, p< 0.05) and back strength with forearm and spine density 
in men (r = 0.46, p < 0.01).(31) Back strength is believed to serve as a predictor o f trunk 
and peripheral BMD in men.(31,47) Additionally, Popcock, et al., observed in post 
menopausal women that:
biceps muscle strength was an independent predictor o f bone mineral 
density in three sites o f the proximal femur (r = 0.56, 0.54 and 0.41, p< 0.001).<48)
Conversely, Sinaki, et al., observed in postmenopausal females undergoing a non-loading
exercise program for back extensor muscles, that improvement in back strength did not
inhibit vertebral resorption (p = 0.002).(39) This disparity between studies may be due to
the fact that the spine is composed mostly of trabecular bone, which is far more sensitive
to estrogen deficiency after menopause ensues. For this reason, exercise with
improvement in strength did not have a protective effect on the spine whereas areas with
higher cortical bone (forearm and femur) did show some protective benefit.
Osteoporosis
Osteoporosis is the primary cause of bone mineral loss in post-menopausal 
females.(3’n ’32,35,36’49'52) According to results from the Mediterranean Osteoporosis Study 
(MEDOS), those individuals at higher risk for development of osteoporosis and 
subsequent fractures are very lean, tall females who currently smoke at least 2 packs of 
cigarettes/day and have a familial history of osteoporosis.(53) This bone disease process 
is defined as loss of structural integrity of the bone due to excessive resorption.<32,54) The
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longitudinal trabeculae have been observed to become thinner while some o f the 
transverse trabeculae are totally resorbed.(29,55) When resorption exceeds formation, the 
integrity o f the bone is affected. This results in weakening of the bone such that it 
becomes brittle and able to endure far less mechanical strain.(55)
Normally in the skeletal system there exists a homeostasis in which bone is either 
lost or laid down in direct response to the experience o f daily mechanical stress.(29,55) 
During early adulthood there is usually a positive balance so that peak bone mass is 
achieved but in later life when estrogen levels decline, a negative balance between bone 
resorption and formation can occur.(31) The time period necessary for completion o f 
initial remodeling through actual bone formation takes approximately 3'A months with 
mineralization requiring an additional 3-4 months.<32,56'58)
A widely accepted method of treatment for the prevention o f bone resorption in 
postmenopausal women is estrogen replacement therapy.(32,59‘65) Type I involutional 
osteoporosis which results in loss o f trabecular bone is secondary to postmenopausal 
estrogen deficiency.(59) It is believed that trabecular bone may be more sensitive to 
estrogen deficiency than cortical bone.(32,68> This may be due to the high surface to 
volume ratio o f trabecular bone, which has a turnover rate eight times that o f cortical 
bone.(69) Loss o f trabecular bone in the Ward’s triangle region o f the proximal femur 
can result in aging-related proximal femur fractures.(68) Sites for increased incidence of 
fracture are the femur and spine with a doubling o f fracture risk for every 10% decrease 
BMD.(48,59’66,67) Decline in vertebral bone density is approximately ten times greater 
during the first five years after menopause onset than at any other time in a woman’s 
life.<69) In particular, accelerated bone loss from the spine in 60 year old women is as
high as 46.8% due to its high content of trabecular bone.(45,67) It is therefore not 
surprising to observe that the highest incidence of fractures due to osteoporosis are 
vertebral with the occurrence of hip fractures having a rate only half as high.(54) The 
major health care costs associated with osteoporosis, however, are related to hip 
fractures due to the associated high morbidity resulting from immobility, which 
ultimately leads to a high mortality rate.(8,48,70’71)
Biochemical Markers
Clinical documentation of excessive bone resorption with resulting osteoporosis 
is often accomplished with the use of numerous biochemical markers o f bone turnover. 
These markers specifically reflect bone formation (osteoblastic activity) and resorption 
(osteoclastic activity). These include serum PTH, urine hydroxyproline calcium and 
phosphorus, reflecting bone resorption.(72) Those specific for bone formation are bone 
specific or total alkaline phosphatase, 25(QH) D3 and osteocalcin.(72)
Serum PTH is known to have a stimulatory effect on bone calcium resorption. 
Mid-molecule rather than carboxy terminal fragments o f PTH have been previously 
observed to be significantly lower in postmenopausal subjects, although this has not 
been a consistent finding.(73) PTH is directly responsible for action on the distal tubules 
to increase renal absorption of calcium as well as increase hydroxylation o f 25(OH) D3 
to the physiologically active form 1,25 (OH)2 D3, which functions as a hormone. 
Activation o f vitamin D3 (to the hormone form) increases intestinal absorption o f 
calcium. High ionized calcium levels are a direct determinant o f lowered serum PTH 
levels through a feedback mechanism.
Plasma bone-GLA protein (osteocalcin) is a specific vitamin K-dependent protein 
which is synthesized by osteoblasts/6,65,73’ Vitamin K is a required co-factor in the 
synthesis, which occurs due to an interaction utilizing glutamate carboxylase and vitamin 
K epoxidase enzymes.(74) According to Gallop, Lian and Hauschka it is the carboxyl 
groups o f the GLA residues, which enable this protein to exhibit calcium-binding 
properties.(74) Osteocalcin has been demonstrated to bind strongly to hydroxyapatite in 
the cow, swordfish vertebrae, bovine dentine and human cortical bone.(75) A positive 
correlation has been observed between serum levels o f bone-GLA protein and lumbar 
BMD measured by CAT scan (r = 0.65, p < 0.001).(73) Osteocalcin is believed to be a 
useful indicator o f bone formation/6’ Currently accepted methods for assay are to 
analyze for intact osteocalcin and the N-mid fragment by radioimmunoassay/72’
Other markers of bone turnover which have been frequently used are 24 hour 
collections o f urine for calcium and phosphorus/6,76’ The fractional excretion o f calcium 
and phosphorusxreatinine is a widely used measure o f renal tubular reabsorption of 
calcium and phosphorus according to Need, et a l.<76)
Pharmacological Treatment and Prevention of Osteoporosis
Numerous studies have been conducted concerning whether improvement in 
bone density in osteoporotic patients occurs as a result of pharmacological therapy. 
Although subjects appear to respond well to preventive treatment, there are inconsistent 
results in those with previously documented bone loss from osteoporosis/49,77'79’ 
Additionally, pharmacological treatment appears to provide no lasting effects. Once 
therapy is discontinued bone mineral density returns to pre-treatment values/76,80,81’ 
Bisphosphonates, calcium, flouride, androgens, synthetic anabolic steroids, estrogen,
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progesterone, calcitonin, vitamin D3 and its metabolites have all been used in treatment 
with varying results and side effects/7,49,51,76,79,82'86’
Anabolic Steroids
Supplementation with androgens and estrogens have been noted to act as: 
“independent additive determinants o f peak bone density.”160’ Improvement in bone 
density has been well documented with anabolic treatment, although the effects diminish 
when treatment is interrupted/61’64’87'91’ The precise mechanism of action o f anabolic 
steroids to increase BMD is unknown. High affinity androgen binding sites have been 
demonstrated in human and rat cell lines with osteoblastic phenotypes/92’
Androgens may influence intestinal responses of l,25(OH)2 D3 to improve 
calcium uptake/93’ Nandrolone decanoate-treated women, with osteoporotic vertebral 
fractures, showed a statistically significant increase in intestinal calcium absorption after 
12 months o f therapy/94’ Increased lean mass, by induction o f protein synthesis in 
skeletal muscle resulting in a positive nitrogen balance, has been clearly documented with 
anabolic steroid treatment/84,95’ Increase in muscle mass and protein content in rats has 
been suggested to be dose-dependent/96’ In rabbit studies, increased wet muscle weight 
and CSA in limb muscles was documented after 12 weeks of anabolic treatment/97’ Due 
to the previous positive effects observed with muscle mass in the scientific literature, 
evaluation o f potential changes in muscle CSA was of particular interest and included in 
the methodology of the present core study, as well as in this investigation. The question 
o f whether a direct relationship exists between increased lean mass and BMD, without 
exercise, however, remains inconclusive/29,62,98'99’ Doyle’s post-mortem study, however, 
is the only evidence of direct correlation between muscle and bone mass, in terms of
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contractile forces creating biomechanical stress on the skeleton/18) Since many factors 
are believed to be interdependently associated with tightly regulated bone homeostasis 
(resorption and formation), it is understandable that this process requires further 
investigation.
Anabolic steroids have been studied extensively for use in the treatment o f post­
menopausal osteoporosis. Stanozolol, a synthetic anabolic steroid, has been shown to 
stimulate bone formation in conjunction with a decrease in urinary calcium excretion, 
increased urinary cyclic AMP and increased serum skeletal Aik Phos activity/87,100*
There, however, can be a non-uniform skeletal increase in bone mass/49,82* Additionally, 
there is no information available on the quality of mechanical strength and stability o f this 
bone replacement ,(82) Treatment in two studies, 24 and 26 months, respectively, with 
methandrostenolone revealed increased lean mass, prevention of further bone density 
loss but without any increase in BMD in postmenopausal osteoporotic females/49,78* 
Another synthetic anabolic steroid, Org OD 14, has demonstrated increased lumbar bone 
density (8% increase after 24 months of treatment) and it has been suggested to inhibit 
bone resorption and stimulate osteoblastic activity/51* The question of the precise 
mechanism for change in BMD, however, remains controversial and unanswered. 
Nandrolone Decanoate
Nandrolone decanoate (17B-hydroxyestr-4-en-3-one 17-decanoate); Deca- 
Durabolin (Organon, Inc.,West Orange, NJ), the pharmacological treatment for this 
study, has not been previously studied for its prospective role in improvement of 
biochemical markers for bone formation and resulting bone mineral apposition in 
postmenopausal subjects without osteoporosis, although it has been studied in
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osteoporotic patients. Androgens are known to be involved in the determination o f peak 
bone mass in both males and females. There is also strong evidence that testosterone or 
a metabolite is directly responsible for bone development at puberty.(88) It has been 
previously demonstrated that muscular tissues are more responsive to nandrolone 
treatment than other tissues.(101) This is believed to be due to the strong binding 
capability o f nandrolone to androgen receptors, which are located largely in muscular 
tissue.<101) Nandrolone decanoate treatment has resulted in an increase in BMC and 
BMD of the forearm and lumbar spine as well as increased lean mass and decreased fat 
mass in osteoporotic postmenopausal females.*37,62’63,76,93’94* In addition, increase in renal 
tubular calcium reabsorption without activation of skeletal Aik Phos has been 
observed.<93) Others have not observed significant changes in BMD with nandrolone 
treatment, although increases in lean mass and a decline in fat mass were documented.<64) 
It has previously been suggested that increases in BMD from treatment may be related to 
a decrease in bone resorption rather than an increase in bone mass.*63,102,103*
Parenteral administration o f nandrolone decanoate has been associated with 
adverse side-effects. There have been reports of virilizing effects which include 
hirsutism, hoarseness and deepening of the voice.*63,89,I02,104,I05) Others have reported no 
virilizing effects after long-term treatment.*103* A non-significant decline in serum high- 
density lipoprotein cholesterol has also been noted with treatment over a two year 
period.*63* Some androgens have been associated with hepatotoxicity, as observed from 




This chapter has set forth a number of important issues regarding control o f bone 
formation and resorption. It is evident that there are a number o f interdependent factors 
that appear to be associated with bone turnover, some of which have effects on 
resorption, while others may affect formation. Although there is major control by the 
endocrine system, in terms of bone homeostasis, there are other mechanisms which play 
some yet-to-be-defmed role.
One factor which required further clarification was lean mass effects on bone 
density. Information has been presented that defined the anatomical and biomechanical 
relationship between muscle mass, its contractile force during physical activity acting 
upon bone and this action stimulating bone formation. Lanyon’s minimum effective 
strain-related stimulus*29’ adequately encompasses the biomechanical force relationship 
that exists between muscle and bone. Further, Doyle, Brown and Lachance have 
previously demonstrated a strong correlation existed between regional muscle mass and 
bone density.*18’ Their work served to clarify the importance of muscle force, as a result 
o f its mass and contractile strength on bone mass. Also muscle disuse and loss of 
contractile strength has been documented to be adversely correlated with bone mass.
There is no doubt that this biomechanical relationship between bone and muscle 
exists, although the extent to which muscle strength predicts bone mass is unknown. 
Weight-bearing exercise in the form of resistance training, in particular, has been found 
to increase strength, muscle mass and BMD. The theory is that increased muscle 
contractile force may contribute to bone remodeling but the precise definition o f the 
nature o f the exercise, relative contributions of muscular force and mass changes as a
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result of exercise need to be clarified. Dalsky has noted that exercise training may 
increase peak bone mass by as high as 10% when optimal hormonal and nutritional 
conditions exist.(U) It is important to remember, however, when interpreting Dalsky’s 
conclusions that there are many other factors besides exercise that interdependently 
contribute to remodeling, thus influencing bone mass.
Strength testing has demonstrated that isokinetic, isometric and isotonic muscle 
strength have all been correlated to varying degrees with bone density. In addition, 
strength training has resulted in a diversity of responses by bone mass, dependent upon 
the age, sex and type o f training of the subjects. In particular, postmenopausal females 
who improved back strength from an exercise program didn’t inhibit bone loss from the 
spine.(39)
As previously emphasized, it is the postmenopausal female who faces the greatest 
risk for bone resorption, without adequate replacement, to occur. Bone homeostasis is 
no longer guaranteed with the onset of menopause, unless estrogen replacement therapy 
ensues.
One o f the most important aspects of clinical evaluation for bone turnover has 
been the advent o f biochemical markers. These provide significant documentation of the 
current status o f bone formation and resorption in subjects. Additionally, endocrine 
markers and urinary markers for bone and collagen loss have been extremely useful in 
developing a clear picture o f bone status in subjects.
A review of various pharmacological treatments to improve bone density and 
decrease risk for fracture has been presented. Few drugs are currently approved by the 
Food and Drug Administration (FDA) for treatment of osteoporosis, whereas numerous
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ones are in the clinical trials phase. What is not clear with many o f the treatment options 
is the quality of new bone that is formed as a result o f treatment. It is clear, however, 
that positive effects on bone mass are only present with concurrent treatment and once 
treatment is terminated, the positive effects cease. This is also the case with estrogen 
replacement therapy (ERT), as well.
One drug treatment option which is not approved by the FDA for clinical use is 
anabolic steroids. This class o f drugs has, however, been tested in research settings and 
shown to increase BMD in osteoporotic subjects. Of particular interest is the question 
that these drugs may increase vitamin D action on the gut to increase calcium 
absorption.*93* Additionally, it has been discussed that anabolic steroids have been 
demonstrated to increase lean mass. Whether this has direct implications in improving 
BMD is o f importance.
Finally, nandrolone decanoate has been discussed in terms of previous research 
on osteoporotics. It has clearly demonstrated an improvement in BMD and BMC of 
both the forearms and lumbar spine of osteoporotic subjects. Nandrolone decanoate, 
like other steroids, has demonstrated, in certain populations, changes in lean body mass 
and bone similar to effects observed in exercise. This drug posed minimal risk to the 
subjects being tested but due to this possibility, nandrolone was assigned at a lower dose 
range than the osteoporosis treatment literature reflects. Although previous studies 
using anabolic steroids have shown strong evidence of increased lean mass, this 
investigation served to focus on lean mass changes without exercise and whether 
preservation o f BMD in non-osteoporotic females would occur.
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This investigation was needed to focus on the effects of an anabolic steroid on 
muscular force, lean mass, bone density and biochemical and endocrine indicators of 
bone turnover. Results will assist in the understanding o f the inter-relationships o f lean 
body mass, bone density and indicators of osteoblastic and osteoclastic activity.
CHAPTER 3: MATERIALS AND METHODS
This study determined the effects of treatment with 30 mg. nandrolone decanoate 
or a placebo on postmenopausal non-osteoporotic obese females on biomechanical, 
biochemical and endocrine endpoints over a nine-month period. A dosage o f 30 mg. was 
selected, although smaller than the dosage used in the osteoporosis literature, to 
minimize the virilizing side effects which accompany anabolic treatment. All o f the 
dependent variables were selected because of their importance as markers o f bone 
turnover (synthesis or resorption), bone density and mineral content and muscle strength 
status.
Subjects
A group of 20 healthy Caucasian postmenopausal females aged 37-62 were 
recruited from the local and outlying communities by advertisement for the core weight 
loss study. Subjects had a body mass index (BMI= kg/m2) between 28-42. All 
participants were either surgically or naturally postmenopausal, which was confirmed by 
Luteinizing Hormone (LH) levels (> 10 mlU/ml). Subjects were healthy, had normal 
bone density, no evidence of hyperlipidemia, no musculoskeletal limitations, not taking 
ERT or calcium supplementation and were basically sedentary, as documented by a 
physical activity history.(107) Volunteers were asked not to change their level o f physical 
activity over the duration o f the study and were reassessed every three months (0, 3, 6, 
and 9 months) with a physical activity history questionnaire, which quantitated the MET 
hours/week and MET hours/over the past 3 months expended during work and leisure 
time. The study protocol was approved by the Louisiana State University Committee on 
the Use o f Humans and Animals and subjects gave their written consent to participate in
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the study with all of its associated procedures. Subjects also signed a core study 
informed consent which outlined the drug treatment, dosage and potential adverse 
effects due to treatment with an anabolic agent.
All volunteers entering the study completed a stringent screening process which 
included a physical examination, blood pressure assessment and clinical laboratory 
evaluation including a complete blood count (CBC), Chemistry 24 panel, lipid profile, 
fasting insulin and routine urinalysis. All lab work and physical examination results were 
required to be within normal limits for subject inclusion into the study. Eighteen subjects 
completed the study with the two drop-outs being from the nandrolone-treated group. 
These subjects withdrew from the study for medical and personal reasons: one 
developing migraine-like symptoms while the other subject terminated due to personal 
reasons. In both cases, the reported adverse effects were not believed to be related to 
nandrolone treatment.
Body Composition Assessment
Body composition for measurement of lean and fat mass (kilograms) was 
evaluated by dual-energy x-ray absorptiometry (DEXA-Hologic QDR 2000,
Waltham,MA). Anthropometric assessment was done by use of measurement of 
circumferences (waist, hip, and mid-upper arm) and calculation o f the waist:hip ratio. 
The upper arm circumference was assessed using a tape measure on the right arm mid­
way between the acromial and olecranon processes with the elbow bent at a 90 degree 
angle and the palm supinated. The measurement was made with the arm relaxed and a 
retractable inelastic tape measure touching the entire arm circumference but not 
compressing or indenting tissue. Measurement was recorded to the nearest 0.1 cm. The
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waist circumference was measured with the subject standing erect and arms at the sides 
with the natural waist (narrowest part of the torso) exposed. Likewise, the measuring 
tape was placed horizontal around the waist diameter of the subject without compressing 
any tissue and recorded to the nearest 0.1 cm. Finally, the hips were measured with the 
subject standing erect with the arms at the sides and feet together. The examiner 
squatted at the side o f the subject so the level of dorsal protrusion of the buttocks could 
be noted. The measuring tape was placed around the dorsal protrusion of the buttocks 
in a horizontal fashion without causing tissue compression or indentation and the 
measurement was recorded to the nearest 0.1 cm. BMI was calculated from height and 
weight of the subjects (kg/m2). Height was measured with use o f a stadiometer and 
recorded twice, to the nearest 0.5 mm., and averaged. Weight was measured twice and 
averaged, using a Detecto digital scale, which was calibrated quarterly using certified 
weights from the U.S. Bureau of Standards. Measurements were made at baseline and 
after three, six and nine months of treatment.
Bone Mineral Density and Content
Bone mineral density (BMD=gm/cm2) and content (BMC=gm) o f the lumbar 
spine ( L 2 - L 4 )  and bilateral forearms were evaluated b y  DEXA. Serial comparisons were 
made at baseline and after six and nine months of treatment, respectively, with use of the 
compare mode and by matching total area scanned. Lumbar spine scans were all done 
using an anterior-posterior view.(106’I07) Forearm (total radius and ulna) assessment was 
made bilaterally to account for both dominant and non-dominant upper extremities. 
Regions of interest were the ultra distal region and total forearm in an effort to account 
for changes in cortical and trabecular bone in the appendicular skeleton.
29
Daily, the DEXA underwent phantom spine calibration prior to use. Data from 
calibrations were monitored and documented so that the coefficient o f variation (CV) of 
all scans would be within an acceptable range. The DEXA has consistently shown high 
correlation o f precision, long-term reproducibility and longitudinal precision(52’66’108,n0'n3) 
with the dual- and single-photon absorptiometry methods (DPA and SPA).(70’U4'116) The 
limitation o f the DEXA rests with the fact that it does not measure bone volume (cm3), 
but rather area (cm2).(U7)
Isometric Hand Grip Strength
Bilateral hand grip strength was assessed with use of a Jamar hand dynamometer 
(TEC, Clifton, NJ). Maximal isometric voluntary contraction (MIVC) was measured 
bilaterally in newtons o f force by having subjects grip the instrument maximally with 
three repetitions. Subjects were instructed to alternate hand testing so as to provide a 
period o f rest to each hand between maximal contractions. The maximum force 
measured for three contractions was recorded for each hand and then averaged. 
Measurements were made at baseline, and after one, three, six and nine months of 
treatment.
Isokinetic Muscle Strength Measurement
The Cybex II (Lumex, Ronkonkoma, NY) was used to measure isokinetic 
strength o f bilateral elbow and knee flexors and extensors. The quadriceps (rectus 
femoris, vastus lateralis, vastus medialis and vastus intermedius) were the major muscle 
group utilized in testing knee extensors while the knee flexors (biceps femoris, 
semitendinosus and semimembranosus) were the group emphasized for the knee flexors. 
The biceps brachii and the biceps brachioradialis are the major muscles which comprise
the elbow flexors and the triceps brachii were the major focus of the elbow extensors. 
Subjects were required to complete 6 repetitions (reps) at 180 degrees/sec and 60 
degrees/sec. A 10 second rest was given between each rep at 180 degrees/sec and a 30 
second rest was given between each rep at the slower speed. Dynamic calibration of the 
dynamometer was performed by lowering different weights attached to the handle of the 
input shaft o f the dynamometer. This was completed daily before testing o f subjects was 
initiated. Each subject was positioned before testing so that for the extremity being 
tested the joint of interest was aligned with the dynamometer’s axis o f rotation. Peak 
torque(118) (PkTq), mean torque (MnTq) and peak torque/body mass (PkTq/BM) for the 
six reps were measured and expressed as newton-meters at baseline, three, six and nine 
months o f the study. Total work (area under the torque curve) was measured at 
baseline and at nine months for all muscle groups tested.
Thigh Muscle Volume
The cross-sectional area o f the left thigh muscle was measured at baseline and 
every three months as part of this investigation and the core study methodology, with 
use o f computerized axial tomography (CAT) scan (Siemans,DRH, NJ). Measurement of 
the CSA of the thigh 100 cm. below the ischial tuberosities was done with a set scan 
thickness of 8.0 mm. The CSA (cm2) of the muscle was determined with use o f the 
computer software by summing all pixels within a range of 30-80 Houndsfield units. 
Laboratory Methodology
Twenty-four hour urinary calcium and phosphorus to creatinine ratios were 
measured at baseline, and at one, three, six and nine months of the study to observe any 
change in bone turnover patterns.(6,65,U9) Subjects were instructed to keep a food record
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for 24 hours preceding and during the 24 hours o f collection, in order to assess calcium, 
phosphorus and sodium intake. Written guidelines were also given to the subjects 
regarding consuming an intake o f 800 mg of calcium during this time period, in an effort 
to provide some control on their calcium intake during urine collection.
Creatinine was measured with use of the Beckman Synchron CX5 (Beckman 
Instruments, Inc., Brea, CA) using the Jaffe method which creates a creatinine-picrate 
complex and monitors for rate o f change in absorbance.
Urine was acidified by adding 5.0 ml of 6 N HC1 to the 24-hour container, prior 
to collection. Analysis was done using a 1:10 dilution with use of the Perkin Elmer 
P I000 ICP which scanned the chemically specified wavelengths to determine the peak 
area of the urine specimen, specific for calcium and phosphorus. Additionally, at 
baseline and every three months, measurements of serum osteocalcin, parathyroid 
hormone (PTH), 25 (OH) D and total Aik Phos were completed. Total Aik Phos was 
measured using the Beckman Synchron CX5 using an enzymatic rate method. Serum 
osteocalcin and 25 hydroxyvitamin D3 were analyzed in duplicate by using a 
radioimmunoassay method (RIA, INCSTAR), while PTH was assessed using a 
immunoradiometric assay (IRMA) (INCSTAR, Stillwater, Minn.).<6,65) These assays 
were read using a RIASTAR 20 well gamma scintillation counter (Packard Instruments, 
owners Grove, II.). Blood samples were drawn after a 12-hour overnight fast between 
8:00-8:30 A.M. through an indwelling intravenous catheter in the antecubital space. 
Samples were drawn and immediately transferred to a glass evacuated tube. The blood 
was allowed to clot and spun at 1949 rpm for 15 minutes with the serum drawn off
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immediately and aliquoted for the various tests. Samples were frozen at -60 degrees C 
until analysis.
Osteocalcin analysis utilized the simultaneous addition of the iced serum sample, 
osteocalcin antibody and 125I osteocalcin, with subsequent overnight incubation for lb- 
24 hours. Following phase separation, centrifugation, decantation and a 2 hour + 15 min 
incubation at 2-8 degrees C, the tubes were read for 60 seconds.(64,72)
Vitamin D was a two-step procedure involving the rapid extraction o f 25(OH) 
D3 and its hydrOxylated metabolites from the serum sample. Following this, the sample, 
tracer and 25(OH)D antibody were incubated for 90 minutes at 20-25 degrees C. There 
was a subsequent addition of a precipitating complex and re-incubation. Following 
centrifugation and decantation, the supernate was read. 25(OH) D3 was selected 
because it is the predominant circulating form of the vitamin and is referenced as the 
most reliable index of vitamin D status.(120)
PTH utilized an assay with two polyclonal antibodies which are specific to PTH 
1-34 (C-terminal region) and 39-84 (mid-region). Iced serum samples were incubated 
with the N-tact PTH SP bead for 22 + 2 hours at 20-25 C. Following this, the sample 
was decanted with the beads washed four times and the intact PTH bound to the SP bead 
was counted. These biochemical and endocrine markers (serum osteocalcin, total Aik 
Phos, PTH, 25(OH) D3 as well as urinary calcium and phosphorus/creatinine), in this 
study were selected in an effort to clearly document any patterns of change in bone 
turnover as a result of anabolic steroid treatment in the subject sample.
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Experim ental Design and Statistical Analysis
This out-patient parallel group design with repeated measures involved a nine 
month period of double-blind drug or placebo treatment, depending upon randomized 
group assignment of 20 subjects. Eighteen subjects completed the study. It was part of 
a larger study assessing the energy expenditure, insulin action and abdominal and total 
body fat loss secondary to treatment with nandrolone decanoate, placebo or aldactone 
with hypocaloric diet in 30 moderately obese post-menopausal females.
The dependent variables in this study were examined utilizing an analysis o f 
variance (ANOVA) with repeated measures where there was a 1 between-subjects factor 
(nandrolone drug treatment) and 1 within-subjects factor (time). In situations where the 
data violated the ANOVA assumption o f sphericitity the corresponding p-values were 
corrected using the Hunyh-Feldt adjustment. Post-ANOVA analysis involved a series of 
1 degree of freedom contrasts (selected a prioi) or simple ANOVAs depending on the 
effect being probed. Post-ANOVA tests were driven by the appropriate F-test and the 
experimentwise error rate (0.05) was maintained throughout all post-ANOVA tests. The 
time periods selected for re-evaluation of the bone density (baseline, 6 and 9 months) 
were chosen because they were believed to be of a sufficient period to note changes 
because of normal bone metabolic mechanisms.(35,40,41’44’79)
CHAPTER 4: RESULTS 
Summary tables for treatment by time interactions and post hoc analysis results 
are listed below (Tables 1 and 2.). Subject characteristics at baseline and additional time 
by treatment interactions are found in Appendix B.
Table 1. Summary of Treatm ent by Time Interactions




Left MI VC 0.03
Right Elbow Flexors PkTq at 180 dps 0.0003
Right Elbow Flexors MnTq at 180 dps 0.0009
Right Elbow Flexors PkTq/BM at 180 dps 0.002
Left Elbow Flexors PkTq at 180 dps 0.013
Left Elbow Flexors MnTq at 180 dps 0.02
Left Elbow Flexors PkTq/BM at 180 dps 0.03
Right Elbow Flexors MnTq at 60 dps 0.04
Left Elbow Flexors PkTq at 60 dps 0.004
Left Elbow Flexors MnTq at 60 dps 0.02
Left Elbow Flexors PkTq/BM at 60 dps 0.03
Right Elbow Extensors PkTq at 180 dps 0.005
Right Elbow Flexors PkTq/BM at 180 dps 0.014
Left Elbow Extensors PkTq at 180 dps 0.03
Left Elbow Extensors PkTq/BM at 180 dps 0.05
Right Knee Extensors PkTq at 180 dps 0.002
Right Knee Extensors MnTq at 180 dps 0.008
Right Knee Extensors PkTq/BM at 180 dps 0.009
Right Knee Extensors PkTq at 60 dps 0.0003
Right Knee Extensors MnTq at 60 dps 0.002
Right Knee Extensors PkTq/BM at 60 dps 0.004
Right Knee Flexors MnTq at 60 dps 0.03
Right Elbow Flexors Total Work at 180 dps 0.02
Right Elbow Flexors Total Work at 60 dps 0.0004
Left Elbow Flexors Total Work at 60 dps 0.0002




Table 2. Post Hoc Analysis for Treatm ent by Time Interactions
Dependent Variable a PL N
LBM 0.025 NSD BL,3M<6,9M
% BF 0.025 BL>3M BL>3,6,9M
Lumbar BMD 0.025 NSD NSD
Left MIVC 0.025 NSD NSD
Right Elbow Flexors PkTq at 180 dps 0.025 NSD BL<6,9M
Right Elbow Flexors MnTq at 180 dps 0.025 NSD BL<6,9M
Right Elbow Flexors PkTq/BM at 180 dps 0.025 NSD BL<6,9M
Left Elbow Flexors PkTq at 180 dps 0.025 NSD NSD
Left Elbow Flexors MnTq at 180 dps 0.025 NSD NSD
Left Elbow Flexors PkTq/BM at 180 dps 0.025 NSD NSD
Right Elbow Flexors MnTq at 60 dps 0.025 NSD BL<6,9M
Left Elbow Flexors PkTq at 60 dps 0.025 NSD BL<6,9M
Left Elbow Flexors MnTq at 60 dps 0.025 NSD BL<6,9M
Left Elbow Flexors PkTq/BM at 60 dps 0.025 BL<3M BL<6,9M
Right Elbow Extensors PkTq at 180 dps 0.025 NSD BL<9M
Right Elbow Flexors PkTq/BM at 180 dps 0.025 NSD BL<9M
Left Elbow Extensors PkTq at 180 dps 0.025 NSD BL<9M
Left Elbow Extensors PkTq/BM 180 dps 0,025 NSD BL<6,9M
Right Knee Extensors PkTq at 180 dps 0.025 NSD 6M>BL,3,9M
Right Knee Extensors MnTq at 180 dps 0.025 NSD 6M>BL,3,9M
Right Knee Extensors PkTq/BM 180 dps 0.025 NSD 6M>BL,3,9M
Right Knee Extensors PkTq at 60 dps 0.025 BL>3,6,9M NSD
Right Knee Extensors MnTq at 60 dps 0.025 BL>6,9M NSD
Right Knee Extensors PkTq/BM 60 dps 0.025 BL>9M NSD
Right Knee Flexors MnTq at 60 dps 0,025 9M<3,6M NSD
Right Elbow Flexors Total Work 180 dps 0.025 NSD 9M>BL
Right Elbow Flexors Total Work 60 dps 0.025 NSD 9M>BL
Left Elbow Flexors Total Work 60 dps 0.025 NSD 9M>BL
Right Elbow Extensors Total Work 60 dps 0.025 NSD NSD
CSA Thigh 0.025 BL>6,9M NSD
Body Composition
A significant treatment by time interaction was observed for lean body mass and 
% body fat. The nandrolone (N) treated group demonstrated a higher lean body mass 
(LBM) at six months (6M) and nine months (9M) versus at baseline and three months 
(3M). To the contrary, there were no significant improvements in LBM in the PL group 
throughout the study period, rather non-significant losses. Additionally, percent body fat
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(% BF) at 3M, 6M and 9M were significantly reduced versus baseline in the N  group. 
The N group started at baseline with a higher (but not significantly) % BF than placebo 
(PL) and continued to lose until 6M where it plateaued. The PL group significantly 
reduced their % BF at 3M versus baseline but made no additional reductions at 6M and 
9M. Initial changes in body fat presumably occurred due to the hypocaloric diet regimen 
the subjects were assigned to follow throughout the study.
Significant main effects for time were detected for body mass (BM) (p = 0.001), 
body mass index (BMI) (p = 0.0001), arm circumference (AC) (p = 0.0032) and fat mass 
(FM) (p = 0.0001) because the baseline values for both groups were greater than any 
other time point in the study. There were no significant changes observed in the 
waist:hip ratio (WHR) over the course of the study.
In summary, the nandrolone treated subjects increased lean body mass and 
decreased their % body fat over time to a greater extent than the placebo group, 
however, did not lose fat mass significantly different than placebo-treated subjects.
There were no group differences in weight, fat mass, or regional fat distribution as 
expressed by waist:hip ratio and arm circumference. It is important to emphasize that 
the resulting significant decline in % body fat in the nandrolone treated subjects occurred 
due to the increase in lean mass alone.
Bone Mineral Density and Content
There was a significant treatment by time interaction (p = 0.02) for bone mineral 
density (BMD) in the lumbar spine. Post hoc analysis did not detect significant 
differences over time for either group but the significant interaction may be due to a 
slight decline in the BMD at 6M for the N group only. Following this decline, BMD
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values returned to near baseline at 9M. Otherwise, no significant difference was 
observed between the groups for BMD and bone mineral content (BMC) o f the lumbar 
spine.
With respect to the bilateral total forearm (radius and ulna) bone density, the PL 
group demonstrated a significantly higher BMC than the N group at baseline and 
throughout the study (left forearm: F = 7.194, p = 0.0164; right forearm: F = 6.171, p = 
0.0244). A significant main effect for time, across both groups, was observed for both 
BMD of bilateral total forearms and for BMC of the right forearm. This effect was 
explained by the baseline BMD being significantly greater than the 6M and 9M values for 
the right total forearm, while BMD was greatest at baseline versus 6M in the left 
forearm. Additionally, the baseline BMD and BMC were greater than 6M values for the 
left total forearm. There were no detectable differences across time with use of post hoc 
analysis for the right total forearm BMC.
A significant main effect of time was observed for BMD of the right ultra-distal 
(UD) forearm (p = 0.032) and BMC of the left UD forearm region (p = 0.002). These 
effects were accounted for by the larger baseline BMC and BMD values versus 6M.
In summary, nandrolone treatment did not serve to protect or preserve the 
subjects BMD and BMC over PL. In the case o f the total forearm and UD forearm, 
there was loss o f BMD and BMC which occurred in both N and PL groups, signifying 
there were no treatment effects.
Isometric Hand Grip Strength (MIVC)
A significant treatment by time interaction was noted only for the left maximal 
isometric voluntary contraction (MIVC) but not the right. Post hoc testing did not
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detect differences over time for either group, with respect to the left MIVC. The 
interaction was probably caused by the N group grip strength being lower than PL at 
baseline but higher at 9M.
Isokinetic Muscle Strength Measurement
A significant treatment by time interaction was observed for peak torque (PkTq), 
mean torque (MnTq) and peak torque per body mass (PkTq/BM) for bilateral elbow 
flexors at 180 degrees/second (dps). The right elbow flexors torque at 180 dps 
demonstrated a significant increase from baseline to 6M and 9M for all three dependent 
variables for N, as was identified by post hoc analysis. The post hoc analysis, however, 
did not reveal specific differences over time for PL or N-treated groups with respect to 
the left elbow flexors. The interaction for the left elbow flexors data was due to a 
marked increase in the N-group from baseline to 3M and with a continued increase from 
6M to 9M, whereas the PL group did not change significantly over time. Additionally, at 
60 dps there was a significant treatment by time interaction for MnTq o f the right elbow 
flexors caused by the N-treated group with the 6M and 9M torque being greater than 
baseline. The left elbow flexors showed significant treatment by time interaction for all 
three dependent variables, with PL demonstrating no significant change over time from 
the post hoc analysis with N eliciting an increase in torque at 6M and 9M versus 
baseline.
With regard to the right and left elbow extensors, there was a significant 
treatment by time interaction for PkTq and PkTq/BM at 180 dps, while the right elbow 
extensors also showed a time effect for MnTq. The interaction was related to the 
significantly lower baseline PkTq and PkTq/BM versus at 6M and 9M for the left elbow
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extensors for N while the right elbow extensors torque was significantly lower at baseline 
versus the PkTq at 9M. The right elbow extensors at 60 dps demonstrated only a time 
effect for PkTq/BM, for which baseline torque was significantly less than at 6M.
There was a significant treatment by time interaction for PkTq, MnTq and 
PkTq/BM for the right knee extensors at 180 dps. The post hoc analysis revealed that 
the N group PkTq, MnTq and PkTq/BM were significantly greater at 6M than at any 
other time point. There was also a significant treatment by time interaction for PkTq, 
MnTq and PkTq/BM of the right knee extensors at 60 dps. Post hoc analysis noted a 
larger torque at baseline than other time points for PL. Finally, the left knee extensors 
were noted to exhibit a significant effect for time only for PkTq/BM at 180 dps with a 
peak observed at 6M.
Time by treatment effects for the right knee flexor MnTq at 60 dps were detected 
and with post hoc analysis it was determined that the differences occurred in the PL 
group, with a decline in torque over time (9M < 3M and 6M). To the contrary, no 
differences were detected in the N-treated group.
A significant effect for time was demonstrated for bilateral knee flexors PkTq, 
MnTq and PkTq/BM at 180 dps and at 60 dps for the right knee flexors for PkTq, MnTq 
and PkTq/BM. These all revealed that the difference existed at 6M, which was the peak 
response for all the knee flexors values showing significance.
Total work (area under the torque curve) was measured pre- and post study for 
all muscle groups tested at both 180 and 60 dps. A significant treatment by time 
interaction (p = 0 .02) was observed for bilateral elbow flexors at 60 dps and the right 
elbow flexors at 180 dps. Post hoc analysis demonstrated N to show a significant work
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increase for the right elbow flexors at 9M versus baseline (p = 0.025) at both speeds and 
the left elbow flexors at 60 dps. Conversely, PL did not change their total work over 
time.
A treatment by time interaction was also documented for total work of the right 
elbow extensors at 60 dps, however no specific differences could be determined by post 
hoc analysis. This was probably caused by a pattern o f increase in total work from 
baseline to 9M in N. Significant time effects were also observed for the left elbow 
extensors at both speeds, with total work greater at 9M over baseline.
Regarding the lower extremities, significant time effects for both N  and PL 
treated groups were only seen for bilateral knee extensors at 60 dps with baseline work 
being greater than at 9M. No time effects were seen for bilateral knee flexors.
In summary, significant differences with respect to the N treated group were 
observed particularly in the upper extremities over time. Both the left and right elbow 
flexors torque increased over time when tested at 180 dps for N but not PL, whereas 
elbow extensors changes were only based upon time effects. In the lower extremities, 
the PL group demonstrated a decline in torque over time with respect to the right knee 
extensors and knee flexors at 180 and 60 dps. N only revealed a peak at 6M for the right 
knee extensors torque (peak, mean and per body mass). Total work increases were seen 
to a greater extent in the upper extremities. The N group documented significant 
increases for the elbow flexors and the right elbow extensors between pre- and post 
study. Bilateral knee extensors at 60 dps only showed time effects for both groups.
41
Thigh Muscle Volume
A significant treatment by time interaction was noted for cross-sectional area 
(CSA) of the thigh. Post hoc analysis revealed that the baseline volume was greater than 
at 6M and 9M for PL. Conversely, the N-treated group demonstrated a non-significant 
increase in thigh muscle CSA over time.
Endocrine Markers
There were no significant main effects observed for parathyroid hormone (PTH), 
whereas 25 (OH) D3 demonstrated a main effect for time for both groups. This was 
accounted for because vitamin D values for both groups were significantly greater at 
baseline than at any other time point in the study. The mean coefficients o f variation (% 
CV) for these assays were 10.51 and 6.11%, for vitamin D and PTH, respectively. The 
normal ranges in this investigation for vitamin D and PTH were 10.00-50.00 ng/ml and 
13.00-54.00 pg/L, respectively.
Biochemical Markers
There was a significant main effect for time in the urinary calciumxreatinine ratio 
with no specific differences detected between time points. Conversely, the phosphorus: 
creatinine ratio was significantly greater at baseline than at 3M, 6M or 9M. There were 
no significant differences between the PL and N- treated groups for alkaline phosphatase 
(Aik Phos), osteocalcin (OC), and urinary calciumxreatinine and phosphorusxreatinine 
ratios. The mean CV for osteocalcin was 5.14% with a normal range o f 1.80-6.60 
ng/ml. The mean interassay coefficients of variation for urine calcium and phosphorus 
were 0.682% and 2.4%, respectively.
Diet records were kept by the subjects 24 hours preceding and the 24 hours 
during urine collection at baseline, 1M, 3M, 6M and 9M. Subjects received specific 
written and verbal instructions regarding the required information and amounts to be 
documented. Additionally, subjects were instructed to consume 800 mg. o f calcium in 
their daily intake of food, to provide consistency of intake. Review of the records and 
analysis by a nutritional database revealed records were poorly kept by subjects. A 
significant correlation between phosphorus and sodium intake and urinary phosphorus 
excretion was observed at 3M for N. Correlations were r = 0.87, p = 0.001 for 
phosphorus intake and excretion while r = 0.69, p = 0.010 for sodium intake and 
phosphorus urinary loss. No other time points were found to have significant correlation 
for dietary intake and urinary loss of these electrolytes.
CHAPTER 5: DISCUSSION 
This investigation assessed prevention of loss of bone density, with respect to a nine 
month weight loss program, in obese postmenopausal females with normal bone density. 
Weight loss was modest in view of the amount o f weight that could have been lost over 
the course of the study. The discussion focuses on treatment effects from nandrolone in 
this case o f minimal weight loss. Numerous treatment by time effects will be discussed 
which revealed a difference in the pattern of change across time between the placebo and 
nandrolone-treated groups.
The observation of treatment by time effects on lean body mass is compatible with 
results from other investigations that have demonstrated increased lean mass with 
anabolic steroid treatment. The CSA changes of the thigh were consistent with overall 
LBM increases. The nandrolone-treated group demonstrated a non-significant increase 
in muscle mass while PL declined (baseline > 6M, 9M). There was a strong trend for a 
treatment main effect, which reflected muscle mass preservation with nandrolone 
treatment (F = 4.483, p = 0.0514). Conversely, the placebo group demonstrated a non­
significant decline in thigh CSA over nine months.
There was also an expected decline in % BF in both groups which was probably due to 
the hypocaloric diet utilized in the core study. The N group demonstrated a decline in % 
BF until 6M, when a plateau occurred, although 3M, 6M and 9M were all significantly 
reduced from baseline. The PL group also had a significant decline in % BF at 3M and 
6M versus baseline. Subjects appeared to have a loss of interest for participation in the 
calorie restricted phase o f the study before 6M, as reflected by the limited amount of 
weight loss. Unfortunately lack o f diet compliance resulted in minimal weight loss which
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was not near the anticipated goal. The expected weight loss was that subjects BM 
would decline by at least 13.64 kg (30 lb.) during the course of the study so that weight 
loss effects on the postmenopausal skeletal system could be observed. Subjects from the 
N group went from a weight of 87.4 + 8.2 kg at baseline to 84.9 ± 8.7 kg at 9M (a loss 
o f 2.5 kg). The PL group began with a mean weight of 86.7 + 7.5 and completed the 
study at 81.7 + 8.1 kg (a loss of 5 kg). These small changes in body weight were 
reflected in a minimal decline in %  BF and a non-significant decline in LBM until 6M 
when it plateaued in the PL group. N did demonstrate significant improvement in LBM 
and decrease in %  BF. This pattern of change in lean body mass with nandrolone 
treatment was presumably due to the high binding affinity o f this anabolic agent to 
androgen binding receptors in skeletal muscle because of the low a-reductase activity in 
skeletal muscle as reported previously.
There must, however, be a cautious interpretation of the significant decline in % 
body fat from nandrolone treatment. There were no significant differences between 
groups with regard to loss of body fat which means that the decrease in % BF was 
strictly due to the increase in lean mass alone, not to total fat mass losses. Additionally, 
the plateau in the decline in % BF at 6M was concurrent with the plateau in the change 
in LBM for both groups. The hypothesis was partially supported because LBM 
increased significantly and a trend was observed for increased thigh CSA. Since weight 
loss was modest, other body composition changes related to fat mass losses were not 
seen (BMI, FM, BM, AC and WHR).
The treatment by time interaction for lumbar bone density was an important 
observation with technical relevance. Evaluating the data one sees that the spine BMD
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decreased non-significantly at 6M in the N group and returned to near baseline levels at 
9M. The length of time required for osteoblast action and mineralization to occur is a 
minimum of 6-9 months, therefore other possible anatomical factors or a chance 
variation in measurement procedures presumably affected the scan resolution. In terms 
of method, all scans were analyzed in the compare mode and the total area scanned (cm2) 
was matched to the baseline scan. The core study, which assessed subcutaneous and 
visceral abdominal fat changes in the subjects provided the best explanation to this 
phenomenon of decline in BMD at 6M, with return to near baseline levels at 9M. The 
visceral fat in the N group increased significantly from 153 cm2 at baseline to 161 cm2 at 
6M.(28) The BMD finding is consistent with this investigator’s previous observation that 
abdominal thickness is correlated with a decline in resolution o f the DEXA BMD scan in 
the lumbar region.(121) This was previously observed using data from lateral thickness 
measurements and lateral lumbar BMD lumbar scans in this group of subjects (r =
0.516, p < 0.05) and confirmed as a methodological problem by the company that 
manufactures the DEXA. However, they stand by the quality o f A-P lumbar scans as 
being unaffected by abdominal thickness, except in the case of the morbidly obese.
Additionally, a significant decline in BMD o f bilateral total forearm (radius and 
ulna) was observed over time for both groups as reflected by higher baseline versus 6M 
and 9M for BMD of the right forearm and baseline > 6M for the left forearm. A strong 
trend towards significance (p = 0.054) was observed for BMC decline over time for the 
left forearm, while a significant effect for time was noted for BMC of the right forearm.
A trend (p = 0.07) was also noted for a main effect o f time for BMD of the left forearm- 
UD. The overall effect noted was that both groups lost some forearm BMD and BMC
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throughout the investigation, although their results were still well within normal limits 
for the mean for their age and sex.
In the case o f bone density preservation with anabolic treatment, the hypothesis 
was not supported by these data. The increase in LBM observed in the N group 
appeared to have no effect on preservation of cortical bone in the appendicular skeleton, 
as well as trabecular bone in the spine and ultra distal region o f the forearms. Aside from 
the methodological discrepancies of the DEXA, the results demonstrate that nandrolone 
treatment did not serve as a protective measure for maintaining BMD at least during a 9 
month period. Even with significant increases in LBM and PkTq, MnTq and PkTq/BM 
in isokinetic work, there was no increase nor preservation of baseline BMD and BMC. 
These results are inconsistent with those of Popcock, et al, who observed muscle 
strength to serve as a strong predictor for BMD in the femur and forearm.(48) Popcock 
studied healthy women who did not vigorously exercise, with an average age o f 45 years. 
He concluded that bone loss in the proximal femur may be modulated by muscle 
strength, body mass and physical fitness of the subject.(48) These, of course are issues 
related to chronic mechanical loading to facilitate remodeling. Although the small 
increases in LBM from the current investigation, did not result in any positive effects on 
BMD, it would be interesting to observe whether larger increases in LBM as a result of 
drug treatment and exercise could modulate BMD.
One important consideration to the process of bone remodeling is exercise. The 
subjects in this study were prohibited from increasing their exercise regimen. It is 
plausible that the muscle biomechanical effects on the skeletal system might have been 
greater if subjects had been allowed to physically train, in conjunction with the drug
treatment regimen. Increased physical training was, however, viewed as a possible 
confounding factor and therefore carefully controlled in the subjects through the course 
o f the study. It is also important to note that since the expected weight loss did not 
occur, there was less of a real test to skeletal system remodeling in an estrogen deficient 
sample population. Additionally, the nandrolone dosage utilized in this investigation was 
lower than reported in the literature as having positive effects on BMD in osteoporotics. 
It is conceivable that this may have been a suboptimal dosage, which would not elicit the 
expected effects on the skeletal system. However, serious consideration would have to 
be given before increasing the dosage since even at this treatment level some subjects 
demonstrated virilizing effects.
Another consideration which must be addressed is that these subjects began the 
study with normal BMD and BMC in the lumbar spine and forearm regions, even though 
they were estrogen deficient. Nandrolone decanoate has been used in clinical trials for 
treatment of osteoporotics in which subjects initiated treatment with BMD significantly 
below the mean for their age and sex. Therefore, even small changes in BMD in 
reported samples would be significant. Conversely, the sample in the present 
investigation began with an above average BMD presumably due to their obesity. In this 
population, changes in LBM and strength did not effect any change in BMD.
Additionally, if exercise had been a concurrent part of the treatment regimen with 
nandrolone it is not known whether a resulting increase or preservation of BMD would 
have been observed. It is also not known what effects this treatment regimen would 
have demonstrated in subjects with an initial low BMD.
The association between higher BMD and obesity has previously been attributed 
in the literature to several possible mechanisms. First, it has been suggested that in 
overweight subjects aromatization of androstenedione to estrone occurs in subcutaneous 
adipocytes, which may serve to keep the subject in an estrogen sufficient state.(120,121) 
Although adrostenedione and testosterone both decrease with the onset o f menopause 
(1800 to 750 pg/ml and 300 to 250 pg/ml, respectively) total estrogen production may 
actually be greater in the obese over the slender subject.(123’124) This effect is presumably 
even more predominant with obese postmenopausal subject since extraglandular 
formation of estrone from androstenedione is the primary route o f conversion for this 
hormone.(124) Additionally, increased LBM to support the greater fat mass in the obese 
may also serve as a larger biomechanical force on the skeleton, which could have 
resulting effects on facilitating higher BMD and BMC.
In this investigation the left hand grip MIVC treatment by time interaction for the 
N-group showed an increase in isometric strength between the 6M and 9M time points, 
whereas PL showed no significant change over time. Of interest is that this increase was 
only observed with the left hand and not the right. This may have been reflective of a 
non-dominant side strength increase as a result o f anabolic steroid treatment as well as 
the N group beginning at baseline with a lower grip strength than the PL group and 
increasing past PL values at 9M. These data support the hypothesis due to 
improvement in strength.
Isokinetic muscle strength data demonstrated increases in elbow flexors and 
extensors torque over time with nandrolone treatment. Bilateral elbow flexors extensors 
increased in torque production over time with both speeds (180 and 60 dps). Post hoc
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analysis did clearly demonstrate a significant response over time for torque production of 
N versus the PL group.
Upper extremity total work also increased between pre- and post study for N 
with respect to the right elbow flexors at both speeds and left elbow flexors at 60 dps. 
There was also an observed trend for significance for treatment by time interaction for 
the left elbow flexors and right elbow extensors at 180 dps at 60 dps with 9M being 
greater than baseline (p = 0.059 and 0.07, respectively).
The right knee extensors also demonstrated an increase torque over time, using 
180 dps, with the greatest torque for the N group observed at 6M. Why the torque 
production declined after 6M is not clear, although it is possible the drug treatment 
effects were maximized by 6M and declined without concurrent exercise training. At 60 
dps, for all strength related variables only the PL group were observed to decline in 
torque over time with baseline having the largest value and the N group was noted to 
have no significant differences. The right knee flexors, alone, were observed to decline 
in torque significantly for the PL with no effects on N. To the contrary bilateral knee 
extensors demonstrated increased work over time only at 60 dps with no changes seen 
for the knee flexors.
Overall, nandrolone treatment was associated with small but consistent increases 
in muscle torque production, which supported the hypothesis o f expectation o f increased 
torque production with nandrolone treatment, whereas PL torque remained 
approximately the same or decreased over time. Whether the nandrolone-treated group 
increases in LBM resulted in hypertrophy of muscle tissue, as well as increases in 
connective tissue in these subjects is unknown. Resistance exercise characteristically has
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been associated with increased gains in strength, particularly when combined with 
anabolic steroid treatment.(25) Although resistance exercise is associated with increases 
in LBM for the specific areas trained, change in % BF is not seen with anaerobic 
exercise. Subsequent studies could include resistance exercise in combination with 
calorie restriction and anabolic steroid treatment to facilitate increases in LBM and 
torque production. Thus, new RNA and resulting protein synthesis would effect 
increases in LBM and torque production. These factors could then interact with the 
skeletal system to facilitate bone formation during remodeling.
Possibly, the lack of consistency in torque production (particularly in the lower 
extremities) resulted in the large standard deviation for the means for isokinetic testing 
and was responsible for lack of consistent increases in torque in all extremities tested. 
Many of the subjects had no conception of what a maximal effort meant because they 
were generally very sedentary and most had never been involved in a training program or 
fitness testing.
Regardless of the lack of effect on bone formation, improvements in torque 
production occurred from treatment with nandrolone. These changes, alone could be 
beneficial to many in the elderly population. The long-term result o f no treatment 
effects on bone density may have been related to the following: variation in torque 
production between subjects, the major time by treatment effects appearing only in the 
upper extremities and no chronic training of the muscles via exercise. In addition, there 
was no preservation of bone mass in the forearms even though elbow flexors-elbow 
extensors torque did improve over time in the N treated group. In particular since 
subjects were not participating in exercise training, effects from the increase in LBM
51
were minimized. This was clearly evident in terms of the positive changes observed in 
torque production of the upper extremities without changes in forearm BMD. Small 
differences in BMD over time presumably could have been detected by the DEXA if they 
existed. Short-term precision for DEXA of the spine has been observed to be 1.08%, 
with long-term precision as low as 1.01%.(112)
Nandrolone treatment produced a non-significant increase in the thigh muscle 
volume, whereas the PL subjects lost CSA over time. The occurrence o f a strong trend 
(F = 4.48, p = 0.0514) for group effects was observed. Unfortunately, data for one of 
the N subjects at 9M was lost by the diagnostic facility where the CAT scans were 
completed and analyzed. This left only n = 7 to be statistically analyzed for 9M and this 
particular subject had shown a clear increase in CSA over time up to 6M. Perhaps if the 
data for this subject had been included, statistically significant differences could have 
been documented. Due to the lack o f documentation of statistically significant 
differences between groups, the hypothesis was not supported with respect to these data.
If exercise training had been permitted possibly there would have been a further 
increase in muscle volume, as well as peak torque production due to hypertrophy of the 
muscle tissue. In particular, resistance exercise training using a high strain rate and a low 
number o f repetitions would have potentially yielded positive results in terms of both 
muscle and bone mass. Naturally, aerobic exercise would also be a necessary part o f the 
program to facilitate weight loss, since resistance exercise is not associated with those 
benefits.
With respect to the endocrine markers, 25 (OH) D3 was the only one to 
demonstrate a change from baseline values. This decrease from baseline can be readily
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attributed to the seasonal variation which normally occurs in vitamin D as less is 
produced in the skin during the winter months. Subjects were initially screened and 
entered the 9 month study during the summer and were followed through the fall, winter 
and completed all study requirements in the spring.
It was anticipated that preservation of bone calcium and phosphorus associated 
with nandrolone treatment would occur resulting in a decline in these minerals lost in the 
24-hour urine samples. Specifically what was seen was a significant decline in 
phosphorus:creatinine ratio at 9M versus all other time points. Although a main effect 
for time for both groups was demonstrated for the calcium:creatinine ratio, no significant 
differences were noted with post hoc analysis. Contrary to the findings in this 
investigation with non-osteoporotics, Need demonstrated a decrease in calcium loss in 
the urine with nandrolone treatment of osteoporotics.(93) It is important to remember that 
urinary electrolyte losses can be reflective of dietary intake as well as accounting for 
bone resorption. This relationship was demonstrated with the 3M phosphorus data for 
N. Additionally, there were three trends o f interest related to diet intake and urinary loss 
of minerals. The PL group was observed to show a moderate correlational trend for 
dietary intake o f calcium and sodium with calciuria at baseline (r = 0.56, p = 0.054 and r 
= 0.53, p = 0.064 for calcium intake and sodium intake to calcium urine loss, 
respectively). Also N demonstrated a modest correlational trend related to calcium 
intake and urinary loss at 1M (r = 0.46, p = 0.063) In this specific case, calcium loss in 
the urine did not increase. This is substantiated by the lack of change in osteocalcin 
(OC) and alkaline phosphatase (Aik phos).
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Overall, because there were no effects o f nandrolone treatment on biochemical 
and endocrine markers o f bone turnover these data did not support the hypothesis. The 
small changes in % BF, LBM and muscular torque did not have any effects on bone 
status, nor the bone specific markers which represent the dynamic process o f bone 
resorption and formation. These results conflict with Johansen’s group which 
documented both increases in LBM and BMD in osteoporotic subjects with nandrolone 
treatment,(64) although the current investigation evaluated subjects with normal BMD, 
presumably due to obesity.
In conclusion, the results from this study do not support the hypothesis since the 
nandrolone treated group did not demonstrate bone preservation compared to PL in the 
lumbar spine, bilateral forearms (total radius and ulna) and ultra-distal regions o f bilateral 
forearms. Previously, nandrolone has been observed to have positive effects on bone 
formation in both trabecular and cortical bone of osteoporotic subjects. In this 
investigation, these effects were not documented. A possible reason for lack o f change 
could be too low a dose of the nandrolone (normally administered at 50 mg every 3-4 
weeks) and insufficient treatment time since 6-9 months was the earliest time when 
changes would be observed.
Another issue which may have affected study outcome is that if this study had 
used exercise training within the investigation differences in BMD and BMC when 
combined with anabolic steroid therapy, may have been demonstrated. Anabolic 
treatment combined with minimal weight loss did not have an effect on BMD 
preservation. With exercise, the chronic and repetitive stress to the increased lean mass 
could have resulted in greater hypertrophy and possible hyperplasia of the muscle tissue
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as well as increased recruitment o f fibers. These factors would interplay effecting a
greater peak torque production, thus creating a larger load on the skeletal system. These
greater contractile forces during exercise may have acted on osteoclastic activity to
promote bone remodeling and osteoblastic processes to increase bone formation, since
Lanyon suggests that it is the strain-related stimulation for which the bone cells are not
accustomed that define the character o f the remodeling stimulus of bone.(125'127) It is
evident that anabolic steroid treatment, without exercise, did not mediate this activity
through biomechanical means visavis the different pattern o f change in LBM over the
study for the nandrolone-treated subjects. It is then reasonable to expect exercise
training could have potentiated this effect. Aurbach believes that physical activity may
be a critical factor in determining bone mass for the postmenopausal female:
Thus integral physical load (a function of physical activity, muscle strength 
and weight) may be a determinant of peak bone mass and may thereby help 
to determine the population at risk for osteoporosis. If this concept is 
correct, prophylactic exercise programs (initiated well before menopause) 
should reduce the incidence of fractures.(1)
Additionally, the use of exercise as an integral part o f a weight loss program 
cannot be over emphasized. Although exercise was strictly controlled due to possible 
confounding effects, presumably subjects would have lost a greater amount o f % BF if 
aerobic exercise had been combined with diet and nandrolone treatment.
Let it also be clear that bone homeostasis is not proposed to be rigidly controlled 
only by biomechanical factors. Hormonal interaction to achieve calcium balance is 
critical to bone status and its involvement in this process should not be minimized. In 
terms of biochemical and endocrine markers assessed in this investigation, there were no 
obvious changes in the PTH-Vitamin D axis as a result of treatment. This was also
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reflected in the non-significant changes in Aik Phos, osteocalcin and the urine calcium 
and phosphorusxreatinine ratios throughout the investigation.
Although diet records did show evidence of correlation between intake o f these 
minerals to urinary output this relationship was not statistically significant for most 
collection periods. There was a wide variation in calcium intake of subjects during 
collection periods despite specific written instructions to consume 800 mg./day. The PL 
group consumed a daily range of 184-2006 mg. o f calcium while N intake was in the 
range o f 333 to 1666 mg. over the various collection periods.
Clearly, there were several problems with controlling calcium intake during urine 
collection. First, subjects demonstrated through their food records that they had no 
concept o f calcium sources in whole foods since many did not even meet premenopausal 
RDA requirements for daily calcium consumption. Second, since food records were 
poorly kept, it is possible many foods that were eaten by subjects were not documented 
and calcium, sodium or phosphorus intake may have been higher or even lower. Third, 
even though there was an attempt to control intake for consistency and analysis of 
records for calcium, phosphorus and sodium, there was no evidence o f bioavailability of 
calcium in the gut and whether anabolic steroid treatment had any effects on gut 
absorption o f calcium. If calcium intake was indeed well below RDA standards then this 
may have contributed to bone loss, rather than preservation, with nandrolone treatment. 
This problem has previously been observed in ovariectomized canines treated with 
nandrolone decanoate yet ingesting calcium deficit diets.(128)
Utilization of random urine samples rather than 24-hour collection, which is 
tedious for free-living subjects, is one alternative to obtaining these important data.
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Significant correlations have been demonstrated between these two methods recently (r 
= 0.967, p < 0.0001).<129) Future studies would also do well to assess gut absorption of 
calcium using stable strontium (88Sr) uptake since mechanisms o f vitamin D3 action at 
the level o f the gut with anabolic steroid treatment have never been clarified.
Results from this study do not indicate that nandrolone decanoate, at the dose 
used in this investigation, would serve as a suitable substitute for ERT when estrogen is 
not the appropriate course of treatment due to prior personal and family medical history. 
However, further studies are suggested with this form of drug therapy, if a larger dose 
can be determined to have a greater benefit:risk ratio, for postmenopausal subjects who 
may be placed at risk for increased bone resorption due to weight loss. Since it has been 
shown that osteoblast-like cells have demonstrated in cell cultures to have androgen 
receptors,<92) then continued investigation into this area is highly suggested. It would be 
potentially beneficial for further investigations to combine drug treatment and exercise 
training, as well as providing measures to gain better compliance with hypocaloric diet 
regimen. Larger body weight changes are needed to better test this hypothesis, since 
minimization of weight loss did not sufficiently stress bone status in these women.
Failure of the subjects to reach their target weight is not a new problem in 
treating and studying obesity. Rather, it further emphasizes the need to approach weight 
loss in a realistic manner: calorie reduction, behavior modification and exercise to 
achieve goals o f weight loss. Future studies in the area of postmenopausal women 
undergoing weight loss should remain a very important focus, since these women are at 
greater risk for loss o f BMD. Continued research in the area of pharmacological 
approaches to maintenance of BMD is critical for the postmenopausal female.
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APPENDIX A: INFORMED CONSENT
The Effects of Nandrolone Decanoate, Aldactone 
or Placebo on Muscular Strength,
Biochemical Markers of Bone Formation 
and Bone Mineral Acquisition
I , ___________________________________ , voluntarily consent to participate in
the following investigation which is designed to determine the effects o f nandrolone 
decanoate, aldactone or placebo treatment on improvement in lean body (muscle) mass, 
prevention o f bone mass loss and increased bone density. I understand this is an ancillary 
study to “Synthetic Hormones and Fat Distribution in Obesity” which is assessing 
increased lean mass and fat loss with nandrolone or aldactone treatment.
In deciding to participate in this 9-month study, I understand that I will be 
required to undergo muscle strength testing in my arms and legs at baseline (before drug 
treatment) and after 3, 6, and 9 months of drug or placebo treatment. This will consist 
o f flexing and extending my arms and legs (individually) against a fixed resistance 
throughout the exercise. I understand I will also have grip strength of both hands 
measured by squeezing a device maximally.
I understand I will be required to save a 24-hour urine sample at baseline, 1, 3, 6, 
and 9 month intervals during the study. The purpose o f this is to measure markers in the 
urine for bone formation. I understand I will be required to eat a set amount o f calcium 
in my diet 24 hours prior to urine collection and during the 24 hours I collect urine. I 
understand I will receive specific instructions on calcium intake and urine collection.
I understand I also will be required to have a blood sample analyzed every 3 
months to determine bone formation. I understand this will not require an additional 
venipuncture, rather additional blood (about 1 tsp. extra) will be drawn at the same time 
a sample is drawn for Dr. Lovejoy’s main Synthetic Hormone study.
I understand I will be required to undergo bone density measurements o f both 
forearms and the spine with use o f the DEXA three times during the study (baseline and 
at 6 and 9 months in the study). I understand the radiation exposure from the DEXA is 
40mRem which is not whole body exposure, rather specific only to the regions of 
interest (the spine and forearm). I understand that the radiation exposure from the pre- 
and post-study scans amounts to only 1/3 of the natural background exposure for 1 year.
I understand Pennington Biomedical Research Center is paying for all testing and 
personnel and I am not responsible for any payment. I also understand that in the event
physical injury resulting from research procedures, I would be personally and financially 
responsible to seek medical treatment. I understand that Pennington Biomedical
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Research Center is a research facility only and would not be a source for medical 
treatment.
I understand I am free to withdraw my consent to participate in this study at any 
time. I also understand if I am not compliant with all study procedures, the Principal 
Investigator can terminate my participation in the study.
I understand that through my participation in this study I will be contributing to 
the body of knowledge of biomedical science. I have been informed that the results of 
this study may be published, but my privacy will be protected and my name will not be 
published. I also understand that results from this study will be shared with me once the 
scientific and statistical analysis is complete.
My signature on this sheet indicates that I have completely read this form and 
consent to participate. I will have an opportunity to ask questions prior to the start of 
the study or at any time during the study by contacting the principal investigator, Ellen 
Brooks, R.N., at 765-2560, a co-investigator, Donna Ryan, M.D. at 765-2514 or the 




Ellen R. Brooks, R.N., M.N., Principal Investigator 
Chief, Clinical Research Unit 
Coordinator, Clinical Trials
Jennifer Lovejoy, Ph.D., Co-Investigator
Donna H. Ryan, M.D., Co-Investigator
Associate Executive Director for Science
APPENDIX B: TABLES
Table 3. Group Means for Baseline Dependent Variables
Variable M ean + SD 
Placebo Nandrolone
Body Mass (kg) 86.4 ±7.3 87.1 ± 8 .6
Body Mass Index 33.4 + 2.9 33.9 ±4.3
Lean Body Mass (kg) 41.2 ±4.9 40.1 ±2.5
Fat Mass (kg) 43.3 ±5 .6 43.7 ±6.5
%  Body Fat 49.3 ±4 .6 50.7 ± 2 .9
Waist:Hip Ratio 0.86 ±0.06 0.83 ±0.05
Arm Circumference (cm) 37.4 ±2.5 36.4 ±3.1
CSA Thigh (cm2) 71.1 ± 10.9 71.8 ±6 .8
BMD L2-L4 (gm/cm2) 0.963 ±0.132 0.940 ±0.127
Left Forearm Total BMD
(gm/cm2) 0.562 + 0.620 0.547 + 0.530
Right Forearm Total BMD
(gm/cm2) 0.567 ±0.630 0.544 ±0.520
Table 4. Lean Body Mass (kg) over 9 Months in Subjects Treated with 
Placebo (N=10) or Nandrolone (N=8)
G roun Time Mean + Std. Dev.
PL B/L 41.2 ± 4.9
N B/L 40.1 ±2.5
PL 3M 40.5 ±4.5
N 3M 41.0 ± 2.8
PL 6M 40.0 ±4.5
N 6M 43.1 ±3.3
PL 9M 39.9 ± 4 .4
N 9M 43.0 + 3.8
Time * treatment interaction ANOVA p = 0.0001 
Post hoc analysis: a  = 0.025
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Table 5. Percent Body Fat over 9 Months in Subjects Treated
with Placebo or Nandrolone
Groun Time M ean + Std. Dev.
PL BL 49.3 ± 4 .7
N BL 50.7 + 2.9
PL 3M 46.9 + 5.0
N 3M 47.8 ±4.3
PL 6M 47.1 ± 6 .0
N 6M 45.7 ± 4 .4
PL 9M 47.5 + 5.8
N 9M 45.9 ±5.1
Time * treatment interaction ANOVA p = 0.013 
Post hoc analysis: a  = 0.025
Table 6. Lum bar Bone M ineral Density (gm/cm2! over 9 M onths
Groun Time Mean + Std. Dev.
PL BL 0.963 ±0.132
N BL 0.940 ±0.127
PL 6M 0.974 ±0.138
N 6M 0.910 ±0.100
PL 9M 0.963 ±0.137
N 9M 0.930 + 0.125
Time * treatment interaction ANOVA p = 0.020 
Post hoc analysis: a  = 0.025
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Table 7. Left Maximal Isometric Voluntary Contraction
(Newtons!
GrouD Time M ean + Std. Dev.
PL BL 311.2 + 37.2
N BL 276.2 + 42.6
PL 3M 309.2 + 37.5
N 3M 300.7 + 61.9
PL 6M 300.6 + 36.5
N 6M 286.0 + 55.6
PL 9M 297.1 +48.9
N 9M 313.1 + 52.7
Time * treatment interaction ANOVA p = 0.03 
Post hoc analysis: a  = 0.025
Table 8. Right Elbow Flexors Torque at 180 Degrees per Second 
9 M onths (Newton-Metersl
Groun Time Peak Toraue Mean Toraue Peak Toraue/Bodv Mass
PL BL 19.4 + 2.5 17.1+2.1 0.226 + 0.037
N BL 15.4 + 5.6 13.3+4.7 0.179 + 0.066
PL 3M 18.5+4.5 16.7 + 4.8 0.226 + 0.056
N 3M 18.7 + 3.9 16.6 + 4.0 0.223 + 0.049
PL 6M 18.3+4.6 17.0 + 4.7 0.227 + 0.054
N 6M 20.8 + 3.3 19.1+3.3 0.250 + 0.057
PL 9M 17.9 + 5.0 16.2 + 5.1 0.222 + 0.058
N 9M 21.0 + 5.6 19.4 + 5.8 0.250 + 0.078
Variables are expressed as means ±  std. dev.
Peak torque time * treatment interaction ANOVA p = 0.013 
Mean torque time * treatment interaction ANOVA p = 0.016 
Peak torque/body mass time * treatment interaction ANOVA p = 0.034 
Post Hoc Analysis: a  = 0.025
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Table 9. Left Elbow Flexors Torque at 60 Degrees per Second over 9
 ___________________  Months (Newton-Metersl______________
G roun Time Peak Toraue Mean Toraue Peak Torauc/BM
PL BL 22.5 ±6.2 20.0 ±4 .6 0.260 ±0.067
N BL 20.9 ± 3 .4 18.8 ± 3 .2 0.239 ±0.034
PL 3M 23.6 ±5 .2 21.6 ±  4.3 0.292 ± 0.067
N 3M 24.3 ± 4 .4 22.6 ± 4 .2 0.292 ± 0.057
PL 6M 23.5 ±4 .6 21.6 ±  3.6 0.291 ±0.053
N 6M 26.2 ±6.3 24.0 ± 5 .6 0.310 ±0.075
PL 9M 23.0 ±5 .6 21.0 ± 4.2 0.282 ± 0.065
N 9M 27.5 ±6 .2 25.0 ± 6 .4 0.327 ± 0.086
Variables are expressed as mean ±  std. dev.
Peak torque time * treatment interaction ANOVA p = 0.004 
Mean torque time * treatment interaction ANOVA p = 0.02 
Peak torque/body mass time * treatment interaction ANOVA p = 0.03 
Post Hoc Analysis: a  = 0.025
Table 10. Left Elbow Flexors Torque at 180 Degrees per Second 
 _____________________(Newton-Metersl_________________ _
G roun Time Peak Toraue Mean Toraue Peak Toraue/Bodv Mass
PL BL 19.6 ±5.2 15.9 ± 3.6 0.227 ± 0.063
N BL 17.4 ± 1.9 14.9 ± 2 .4 0.201 ±0.027
PL 3M 19.6 ±4.7 17.3 ±5.0 0.241 ±0.064
N 3M 19.5 ±3.9 17.2 ±3.8 0.235 ±0.047
PL 6M 19.5 ±4.3 17.7 ±  3.9 0.241 ±0.057
N 6M 20.5 ±5.8 17.4 ±5 .6 0.241 ±0.059
PL 9M 18.5 ±3.2 16.2 ±  3.8 0.229 ± 0.043
N 9M 23.4 ±8.6 20.1 +7.5 0.278 + 0.109
Variables are expressed as mean ± std. dev.
Peak torque treatment * time interaction ANOVA p = 0.013 
Mean torque treatment * time interaction ANOVA p= 0.02 
Peak torque/body mass treatment * time interaction ANOVA p = 0.03 
Post hoc analysis: a  -  0.0225
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Table 11. Left Elbow Flexors Torque at 60 Degrees per Second
________________________  (Newton-Meters)________________
Group Time Peak Toraue Mean Toraue Peak Torque/Bodv Mass
PL BL 22.5 ± 6 .2 20.0 ±4 .6 0.260 ± 0.067
N BL 20.9 ±3 .4 18.8 ±3.2 0.239 ± 0.034
PL 3M 24.0 ± 5 .2 21.6 ±  4.3 0.292 + 0.067
N 3M 24.3 ± 4.4 22.6 ±4.2 0.292 ± 0.060
PL 6M 23.5 ± 4 .6 21.6 ±  3.6 0.291 ±0.053
N 6M 26.2 ±6.3 24.0 ±5 .6 0.310 ±0.080
PL 9M 23.0 ±5.7 21.0 ± 4.2 0.282 ±0.065
N 9M 27.5 ±6 .2 25.0 ±6 .4 0.330 ±0.090
Variables are expressed as mean ± std. dev.
peak torque treatment * time interation ANOVA p = 0.004
mean torque treatment * time interaction ANOVA p = 0.02
peak torque/body mass treatment * time interaction ANOVA p = 0.03
Post hoc analysis: a  = 0.025
Table 12. Torque for Right and Left Elbow Extensors at 180 Degrees
____________ per Second over 9 Months (Newton-Metersl ___________________
Right Left
Group Time Peak Toraue Peak Toraue/BM Peak Toraue Peak Toraue/BM
PL BL 17.8 ± 3.5 0.2 ±0.04 16.1 ± 2 .9 0.187 ±0.400
N BL 14.6 ±4.3 0.2 ± 0.05 14.1 ±4.1 0.160 ±0.042
PL 3M 17.1 ±3.4 0.2 ±0.05 16.0 ±4.3 0.200 ± 0.060
N 3M 16.5 ±2.7 0.2 ± 0.04 16.4 ± 4 .2 0.195 ±0.050
PL 6M 17.7 ± 3.2 0.2 ±0.05 16.2 ± 3 .4 0.201 ±0.045
N 6M 18.6 ± 3.5 0.2 ±0.05 17.1 ± 4 .2 0.204 ±0.050
PL 9M 15.9 ±3.2 0.2 ±0.04 15.9 ±3.1 0.197 ±0.036
N 9M 19.0 + 5.6 0.2 + 0.08 18.0 ±  5.2 0.220 + 0.700
Variables are expressed as mean ± std. dev.
Peak torque time * treatment interaction ANOVA p = 0.005
Peak torque/body mass time * treatment interaction ANOVA p = 0.014
Peak torque time * treatment interaction ANOVA p = 0.032
Peak torque/body mass time * treatment interaction ANOVA p = 0.05
(Post hoc analysis: a  = 0.025)
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Table 13. Right Knee Extensors Torque at 180 Degrees per Second
_____________  (N ewton-Meters)____________________
Group Time Peak Torque Mean Torque Peak Torque/Body Mass
PL BL 76.5 ±22.3 70.4 ±21.6 0.885 ±0.255
N BL 67.5 ±9.02 64.1 ±  10.8 0.777 ±  0.093
PL 3M 68.7 ±  16.7 65.5 ±  17.4 0.845 ±0.232
N 3M 66.4 ± 12.1 61.5 ±  14.6 0.795 ±0.156
PL 6M 76.7 ± 18.0 69.5 ±  18.2 0.954 ±0.260
N 6M 88.0 ± 15.6 80.2 ±  15.8 1.054 ±0.238
PL 9M 69.0 ± 19.1 63.8 ±  16.2 0.850 ±0.252
N 9M 72.0 ± 14.7 64.2 ±  16.6 0.853 ±0.184
Variables are expressed as mean ± std. dev.
peak torque treatment * time interaction ANOVA p = 0.02
mean torque treatment * time interaction ANOVA p =0.008
peak torque/body mass treatment * time interaction ANOVA p = 0.009
Post hoc analysis: a  = 0.025
Table 14. Right Knee Extensors Torque at 60 Degrees per Second
__________  (Newton-Meters!___________________________________
Group Time Peak Torque Mean Torque Peak Torque/Bodv Mass
PL BL 115.5 ±24.1 110.2 ±25.0 1.3 ±0 .3
N BL 110.2 ± 19.0 104.0 ± 21.0 1.3 ± 0 .2
PL 3M 107.0 ±25.5 102.0 ±24.2 1.3 ± 0 .4
N 3M 106.0 ±26.0 100.0 ±27.0 1.3 ±0.3
PL 6M 106.0 ±25,0 98.0 ±26.0 1.3 ±0.3
N 6M 116.4 ± 23.0 109.2 ±22.3 1.4 ±0 .3
PL 9M 99.4 ±23.1 93.0 ±22.3 1.2 ± 0 .3
N 9M 115.0 + 22.1 108.3 +23.0 1.4+ 0.3
Variables are expressed as mean ± std. dev.
Peak torque treatment * time interaction ANOVA p = 0.0003 
Mean torque treatment * time interaction ANOVA p = 0.0002 
Peak torque/body mass treatment * time interaction ANOVA p = 0.004
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Table 15. Right Knee Flexors Mean Torque at 60 Degrees per Second
_________  (Newton-Metersl_________________ _____
G roun Time Mean + Std. Dev.
PL BL 70.2 ± 12.8
N BL 69.1 ± 13.9
PL 3M 72.4 ± 12.8
N 3M 66.4 ± 12.7
PL 6M 72.4 ± 14.2
N 6M 76.1 ± 14.0
PL 9M 64.7 ±  10.2
N 9M 71.0 ± 12.0
Mean torque treatment * time interaction ANOVA p = 0.03
Table 16. Right Elbow Flexors Total W ork a t 60 Degrees per Second 
____________________ fNewton-Meters)________ _____________
GrouD Time Mean + Std. Dev.
PL BL 190.6 + 22.7
N BL 174.2+51.9
PL 9M 186.0 + 32.0
N 9M 238.5 + 65.6
Total work treatment * time interaction ANOVA p = 0.0004 
Post hoc analysis: a  = 0.025
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Table 17. Left Elbow Extensors Total W ork a t 180 Degrees per Second
(Newton-Meters)
GrouD Time Mean + Std. Dev.
PL BL 47.5 + 18.0
N BL 43.0+11.1
PL 9M 47.7+12.0
N 9M 57.8 ±21.4
Total work trend for treatment * time interaction ANOVA p = 0.06
Table 18. Right Elbow Extensors Total W ork at 60 Degrees per Second 
______  (Newton-Metersl________________________
GrouD Time Mean + Std. Dev.
PL BL 194.4 + 40.0
N BL 187.4 + 49.3
PL 9M 192.2 + 35.3
N 9M 241.0 ±94.0
Total work treatment * time interaction ANOVA p = 0.014
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Figure 4. Left maximal isometric voluntary contraction treatment by time interaction
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Figure 5. Right elbow flexors peak torque (180 degrees/second) treatment by time





Figure 6. Isokinetic mean torque for right elbow flexors at 180 degrees/second treatment 
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Figure 7. Isokinetic right elbow flexors peak torque/body mass treatment by time
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Figure 8. Left elbow flexors at 180 degrees/second peak torque treatment by time


























Figure 9. Left elbow flexors mean torque at 180 degrees/second treatment by time
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Figure 10. Peak torque/body mass left elbow flexors treatment by time interaction






BL 3M 6M 9M
Month
Figure 11. Mean torque for right elbow flexors treatment by time interaction at 60
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Figure 12. Peak torque at 60 degrees/second treatment by time interaction (p=0.004) for
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Figure 13. Mean torque for left elbow flexors at 60 degrees/second treatment by time
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Figure 14. Peak torque/body mass at 60 degrees/second treatment by time interaction
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Figure 15. Peak torque for right elbow extensors treatment by time interaction (p=0.005)
at 180 degrees/second (Mean ± SD).
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Figure 16. Peak torque/body mass at 180 degrees/second for right elbow extensors 
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Figure 17. Peak torque at 180 degrees/second treatment by time interaction (p=0.03) for
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Figure 18. Peak torque/body mass for left elbow extensors at 180 degrees/second
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Figure 19. Right knee extensors peak torque/body mass at 180 degrees/second treatment
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Figure 20. Mean torque for right knee extensors at 180 degrees/second treatment by time














Figure 21. Peak torque/body mass for right knee extensors at 180 degrees/second
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Figure 22. Peak torque for right knee extensors at 60 degrees/second treatment by time
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Figure 24. Peak torque/body mass for right knee extensors at 60 degrees/second































Figure 25. Mean torque for right knee flexors at 60 degrees/second treatment by time


























Figure 26. Total work right elbow flexors at 180 degrees/second treatment by time


























Figure 27. Total work at 60 degrees/second right elbow flexors treatment by time



























Figure 28. Total work of left elbow flextors at 60 degrees/second treatment by time
interaction (p=0.0002) (Mean + SD).
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Figure 29. Total work at 60 degrees/second right elbow extensors treatment by time















Figure 30. Cross-sectional area of the thigh trend in treatment effects (p=0.()51) (Mean ± 
SD).
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